

CITATION REPORT

List of articles citing

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

DOI: 10.1073/pnas.191367098

Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10869-74.

Source: <https://exaly.com/paper-pdf/32382847/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2209	Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer. 2010 , 4, 53-77		82
2208	A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. 2010 , 4, 167		0
2207	p16 expression correlates with basal-like triple-negative breast carcinoma. 2013 , 7, 317		9
2206	Relationship of CK8/18 expression pattern to breast cancer immunohistochemical subtyping in Egyptian patients. 2014 , 8, 404		3
2205	Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. 1992 , 33, 1239		3
2204	Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. 1992 , 33, 1165		3
2203	Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. 1994 , 20, 987		1
2202	EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. 1994 , 21, 413		4
2201	Stepwise estrogen suppression manipulating the estrostat. 2001 , 79, 127-32		16
2200	Gene expression profiling can distinguish tumor subclasses of breast carcinomas. 2001 , 132-161		1
2199	Molecular profiling in prostate cancer. 2001 , 20, 165-71		6
2198	RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. 2001 , 276, 42259-67		120
2197	Diversity of gene expression in adenocarcinoma of the lung. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 13784-9	11.5	1046
2196	Repuncturing the renal biopsy: strategies for molecular diagnosis in nephrology. 2002 , 13, 1961-72		47
2195	Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 10008-13	11.5	215
2194	Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 12963-8	11.5	980
2193	Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. 2002 , 87, 449-56		23

2192	Binary tree-structured vector quantization approach to clustering and visualizing microarray data. 2002 , 18 Suppl 1, S111-9	51
2191	Analysis of repeatability in spotted cDNA microarrays. 2002 , 30, 3235-44	41
2190	Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. 2002 , 11, 863-72	90
2189	Impact of genomics on medicine. 2002 , 3, 443-6	3
2188	Molecular signatures of breast cancer--predicting the future. 2002 , 347, 2067-8	22
2187	Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. 2002 , 2, 157-90	36
2186	Partial least squares proportional hazard regression for application to DNA microarray survival data. 2002 , 18, 1625-32	282
2185	Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer. 2002 , 9, 207-20	24
2184	cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. 2002 , 23, 1561-8	44
2183	Bayesian automatic relevance determination algorithms for classifying gene expression data. 2002 , 18, 1332-9	118
2182	Pixelating the brain. 2002 , 12, 217-8	6
2181	Selection bias in gene extraction on the basis of microarray gene-expression data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 6562-6	11.5 1066
2180	Development of cDNA microarray for expression profiling of estrogen-responsive genes. 2002 , 29, 175-92	337
2179	Gene expression analysis using cDNA microarrays. 2002 , Chapter 4, Unit 4.28	3
2178	Microarray analysis in prostate cancer research. 2002 , 12, 395-9	21
2177	Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. 2002 , 15, 1374-80	135
2176	Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. 2002 , 161, 665-72	96
2175	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. 2002 , 161, 1223-33	133

2174	Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. 2002 , 161, 1557-65	180
2173	Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. 2002 , 161, 1991-6	453
2172	Microarrays in pharmacogenomics--advances and future promise. 2002 , 3, 589-601	37
2171	The European experience with docetaxel in the treatment of early-stage breast cancer. 2002 , 3 Suppl 2, S59-62	2
2170	A gene-expression signature as a predictor of survival in breast cancer. 2002 , 347, 1999-2009	5020
2169	Algorithms in Bioinformatics. 2002 ,	3
2168	Expression profiling to predict outcome in breast cancer: the influence of sample selection. 2003 , 5, 23-6	32
2167	The importance of being a myoepithelial cell. 2002 , 4, 224-30	113
2166	Defining the galaxy of gene expression in breast cancer. 2002 , 4, 141-4	13
2165	Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. 2002 , 4, R3	155
2164	Microarrays and molecular markers for tumor classification. 2002 , 3, comment2005	12
2163	Biomedical imaging in the postgenomic era: opportunities and challenges. 2002 , 9, 999-1003	7
2162	Perspective: microarray technology, seeing more than spots. 2002 , 143, 1983-9	43
2161	DNA microarrays: implications for clinical medicine. 2002 , 15, 275-9	11
2160	Apoptosis: a link between cancer genetics and chemotherapy. 2002 , 108, 153-64	1883
2159	Gene-expression profiling and identification of patients at high risk of breast cancer. 2002 , 360, 173-4; author reply 174	11
2158	Using cancer genetics to guide the selection of anticancer drug targets. 2002 , 2, 366-73	39
2157	Gene Expression Patterns in Breast Cancer May Identify Specific Tumor Phenotypes and Predict Disease Outcome. 2002 , 3, 240-242	

2156	Functional genomics and the breast cancer problem. 2002 , 1, 15-7	17
2155	Recent developments in DNA microarrays. 2002 , 5, 334-7	68
2154	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. 2002 , 28, 275-90	6
2153	Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves. 2002 , 48, 1321-1328	23
2152	Application of Microarrays to the Analysis of Gene Expression in Cancer. 2002 , 48, 1170-1177	116
2151	Molecular profiling in prostate cancer. 2002 , 29-35	
2150	DNA microarrays in clinical oncology. 2002 , 20, 1932-41	283
2149	Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. 2002 , 23, 139-45	49
2148	Fast forwarding pharmacogenomics. 2002 , 3, 281-5	
2147	Pharmacogenomic biomarkers. 2002 , 18, 63-71	9
2146	The progressing clinical utility of DNA microarrays. 2002 , 52, 50-9	16
2145	Sources of variability and effect of experimental approach on expression profiling data interpretation. 2002 , 3, 4	138
2144	Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. 2002 , 3, 31	105
2143	Molecular markers in the diagnosis and staging of breast cancer. 2002 , 12, 305-18	5
2142	The FLEXGene repository: exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post-genomic era. 2002 , 33, 318-24	36
2141	Computational selection of distinct class- and subclass-specific gene expression signatures. 2002 , 35, 160-70	45
2140	Optimal gene expression analysis by microarrays. 2002 , 2, 353-61	128
2139	News in brief. 2002 , 7, 93-97	

2138	Toxicogenomics: a new revolution in drug safety. 2002 , 7, 728-36	57
2137	Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. 2002 , 115, 142-9	18
2136	Highlight: BRCA1 and BRCA2 proteins in breast cancer. 2002 , 59, 68-83	11
2135	Attributable risks for familial breast cancer by proband status and morphology: a nationwide epidemiologic study from Sweden. 2002 , 100, 214-9	40
2134	Are there two sides to colorectal cancer?. 2002 , 101, 403-8	587
2133	A study of estrogen signaling using DNA microarray in human breast cancer. 2002 , 9, 308-11	15
2132	Symposium 15: Expression and profiling in surgical pathology. 2002 , 41, 249-262	0
2131	Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. 2002 , 21, 7593-7	68
2130	Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. 2002 , 21, 8310-9	29
2129	Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. 2002 , 82, 1525-33	194
2128	Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells. 2002 , 82, 1715-24	33
2127	Gene expression profiling predicts clinical outcome of breast cancer. 2002 , 415, 530-6	7432
2126	Options available--from start to finish--for obtaining data from DNA microarrays II. 2002 , 32 Suppl, 481-9	221
2125	From patterns to pathways: gene expression data analysis comes of age. 2002 , 32 Suppl, 502-8	444
2124	Molecular portraits and the family tree of cancer. 2002 , 32 Suppl, 533-40	223
2123	The microarray way to tailored cancer treatment. 2002 , 8, 13-4	41
2122	Opinion: Interpretation of the complexity of innate immune responses by functional genomics. 2002 , 2, 881-9	94
2121	Prognosis of breast cancer and gene expression profiling using DNA arrays. 2002 , 975, 217-31	31

2120	The enzymatic inactivation of the fatty acid amide class of signaling lipids. 2002 , 121, 135-48	108
2119	Associations between gene expressions in breast cancer and patient survival. 2002 , 111, 411-20	72
2118	Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. 2002 , 76, 27-36	408
2117	Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. 2002 , 76, 221-36	53
2116	Micronutrients in cancer chemoprevention. 2002 , 21, 217-30	54
2115	NF-kappaB and breast cancer. 2002 , 26, 282-309	57
2114	Differential Gene Expression Analysis by DNA Microarray Technology and Its Application in Molecular Oncology. 2003 , 37, 486-494	8
2113	Expression profiling of human breast cancers and gene regulation by progesterone receptors. 2003 , 8, 257-68	44
2112	Interrogating mouse mammary cancer models: insights from gene expression profiling. 2003 , 8, 321-34	10
2111	Laser capture microdissection and advanced molecular analysis of human breast cancer. 2003 , 8, 335-45	37
2110	Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. 2003 , 442, 271-7	110
2109	Microarrays: new tools for transplantation research. 2003 , 18, 319-27	17
2108	Classification of Dukes' B and C colorectal cancers using expression arrays. 2003 , 129, 263-71	78
2107	Profiling cancer. 2003 , 15, 213-20	12
2106	Histopathology of primary breast cancer 2003. 2003 , 12, 391-6	8
2105	Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness. 2003 , 12, 529-37	7
2104	Preoperative systemic treatment: prediction of responsiveness. 2003 , 12, 538-42	26
2103	Cancer pharmacogenomics: current and future applications. 2003 , 1603, 99-111	37

2102	Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues. 2003 , 27, 405-11	14
2101	Tumor classification and marker gene prediction by feature selection and fuzzy c-means clustering using microarray data. 2003 , 4, 60	53
2100	Statistical significance for hierarchical clustering in genetic association and microarray expression studies. 2003 , 4, 62	20
2099	Collagen gel contraction serves to rapidly distinguish epithelial- and mesenchymal-derived cells irrespective of alpha-smooth muscle actin expression. 2003 , 39, 297-303	2
2098	Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. 2003 , 147, 28-35	38
2097	Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. 2003 , 97, 2960-71	157
2096	TP53 and breast cancer. 2003 , 21, 292-300	226
2095	Familial risk of cancer by site and histopathology. 2003 , 103, 105-9	77
2094	Breast cancer revisited using DNA array-based gene expression profiling. 2003 , 103, 565-71	46
2093	Simultaneous classification and relevant feature identification in high-dimensional spaces: application to molecular profiling data. 2003 , 83, 729-743	50
2092	Cancer classification using gene expression data. 2003 , 28, 243-268	160
2091	DNA microarray for discrimination between pathogenic 0157:H7 EDL933 and non-pathogenic Escherichia coli strains. 2003 , 19, 1-8	35
2090	p63 expression in sarcomatoid/metaplastic carcinomas of the breast. 2003 , 42, 94-5	34
2089	Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. 2003 , 36 Suppl 1, 33-44	47
2088	Regulation of human breast epithelial stem cells. 2003 , 36 Suppl 1, 45-58	93
2087	Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. 2003 , 36 Suppl 1, 73-84	106
2086	Abnormal chromosome 8 copy number in cytological smears from breast carcinomas detected by means of fluorescence in situ hybridization (FISH). 2003 , 14, 5-11	13
2085	WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. 2003 , 201, 204-12	286

2084	Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. 2003 , 94, 864-70	23
2083	Screening of stress enhancer based on analysis of gene expression profiles: enhancement of hyperthermia-induced tumor necrosis by an MMP-3 inhibitor. 2003 , 94, 644-9	21
2082	Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. 2003 , 88, 510-5	75
2081	Disease proteomics. 2003 , 422, 226-32	845
2080	Identification of molecular subtypes of glioblastoma by gene expression profiling. 2003 , 22, 2361-73	226
2079	cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. 2003 , 22, 2680-8	131
2078	Gene-expression profiling in human cutaneous melanoma. 2003 , 22, 3076-80	97
2077	Gene expression profiling identifies molecular subtypes of gliomas. 2003 , 22, 4918-23	241
2076	Biologic and therapeutic role of HER2 in cancer. 2003 , 22, 6570-8	304
2075	Advantages and limitations of microarray technology in human cancer. 2003 , 22, 6497-507	204
2074	DNA arrays in clinical oncology: promises and challenges. 2003 , 83, 305-16	32
2073	Identifying distinct classes of bladder carcinoma using microarrays. 2003 , 33, 90-6	401
2072	Chromosome aberrations in solid tumors. 2003 , 34, 369-76	603
2071	Road map to metastasis. 2003 , 9, 999-1000	83
2070	Analysing differential gene expression in cancer. 2003 , 3, 869-76	109
2069	Clinical biomarkers in drug discovery and development. 2003 , 2, 566-80	583
2068	Sequence-based cancer genomics: progress, lessons and opportunities. 2003 , 4, 409-18	52
2067	Chromatin as a tool for the study of genome function in cancer. 2003 , 983, 5-21	21

2066	Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). 2003 , 983, 142-50	43
2065	Enabling inverse metabolic engineering through genomics. 2003 , 14, 484-90	24
2064	Application of microarray technology in environmental and comparative physiology. 2003 , 65, 231-59	141
2063	The c-myc x E2F-1/p21 interactive gene expression index augments cytomorphologic diagnosis of lung cancer in fine-needle aspirate specimens. 2003 , 5, 176-83	12
2062	Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. 2003 , 3, 635-47	32
2061	Transgenic models are predictive: the herceptin and flavopiridol experience. 2003 , 5, 1	78
2060	Protein expression profiling arrays: tools for the multiplexed high-throughput analysis of proteins. 2003 , 1, 3	29
2059	From peas to "chips" - the new millennium of molecular biology: a primer for the surgeon. 2003 , 1, 21	3
2058	Prognostic and predictive indicators in operable breast cancer. 2003 , 3, 381-90	28
2057	High-throughput analysis of total RNA expression profiles by capillary gel electrophoresis. 2003 , 75, 4415-22	12
2056	Tissue microarray study for classification of breast tumors. 2003 , 73, 3189-99	31
2055	Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. 2003 , 163, 2383-95	115
2054	Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. 2003 , 162, 391-402	232
2053	The molecular detection of micrometastatic breast cancer. 2003 , 186, 351-8	20
2052	Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. 2003 , 202, 219-30	106
2051	Gene expression profiling of breast carcinomas using nylon DNA arrays. 2003 , 326, 1031-9	3
2050	Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?. 2003 , 113, 821-3	139
2049	DNA microarrays in breast cancer: the promise of personalised medicine. 2003 , 361, 1576-7	47

2048	Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. 2003 , 362, 362-9		708
2047	HER2 and surgery: more questions to answer. 2003 , 362, 502-3		4
2046	Repeated observation of breast tumor subtypes in independent gene expression data sets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8418-23	11.5	4262
2045	Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. 2003 , 95, 1482-5		737
2044	Mathematics and oncology: a match for life?. 2003 , 21, 1425-8		42
2043	The potential of DNA microarrays for the care of children. 2003 , 142, 235-9		
2042	Classification of cancers by expression profiling. 2003 , 13, 97-103		50
2041	Exploiting the hallmarks of cancer: the future conquest of breast cancer. 2003 , 39, 1668-75		102
2040	Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. 2003 , 30, 256-68		1507
2039	Global functional profiling of gene expression. 2003 , 81, 98-104		479
2038	Transcriptional regulators in mammary gland development and cancer. 2003 , 35, 1034-51		41
2037	Study of suboptimum treatment response: lessons from breast cancer. 2003 , 4, 177-85		49
2036	Classifying human cancer by analysis of gene expression. 2003 , 9, 5-10		21
2035	Gene Expression Profiling to Predict Outcome of Chemotherapy for Early-Stage Breast Cancer. 2003 , 4, 176-178		
2034	Estrogen and growth factor signaling pathway: basic approaches for clinical application. 2003 , 86, 433-42		12
2033	Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 2003 , 86, 301-7		38
2032	Microarrays bring new insights into understanding of breast cancer metastasis to bone. 2004 , 6, 61-4		31
2031	CTLA-4 based therapy (MDX-010). 2003 , 5, 1		78

2030	The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. 2003 , 5, 320-8	18
2029	Microarray technology and its effect on breast cancer (re)classification and prediction of outcome. 2003 , 5, 303-4	13
2028	42nd Annual Meeting of the American Society for Cell Biology, San Francisco, California, USA, 14-18 December 2002. 2003 , 5, 147-53	2
2027	Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. 2003 , 5, 101-6	169
2026	Combined hormonal therapy for advanced breast cancer in postmenopausal patients. 2003 , 5, 1	78
2025	Clinical applications of Affymetrix Genechip arrays for RNA and DNA analysis. 2003 , 5, 1	78
2024	From gene expression patterns to antibody diagnostics. 2003 , 5, 1	78
2023	Rational engineering of Fc/Fc receptor interactions to improve antibody potency. 2003 , 5, 1	1
2022	Target discovery in the postgenomic era. 2003 , 5, 1	78
2021	Genomic approaches to drug target discovery using mouse models. 2003 , 5, 1	4
2020	VelociGene: a high-throughput approach for functionizing the genome via custom gene mutation and high-resolution expression analysis in mice. 2003 , 5, 1	78
2019	Meta-analyses of transcriptional information: impact of data integration in understanding human breast cancers. 2003 , 5, 1	1
2018	Mouse models for pretesting of immunotherapeutic strategies for cancer patients. 2003 , 5, 1	78
2017	Immunotherapy of cancer. 2003 , 5, 1	78
2016	Prevention of breast tumor angiogenesis and metastasis by cytostatic molecules in relevant mouse models. 2003 , 5, 1	1
2015	Functional characterization of mammary stem cells in development and breast cancer. 2003 , 5, 1	78
2014	Stem cells in normal breast development and breast cancer. 2003 , 5, 1	7
2013	Characterization, isolation and cultivation of distinctive human breast cell populations. 2003 , 5, 1	78

2012	Regulation of human mammary stem cells. 2003 , 5, 1	1
2011	In situ to invasive carcinoma transition: escape or release. 2003 , 5, 1	78
2010	Premalignancy in the human breast: how is it defined, is morphology good enough?. 2003 , 5, 1	78
2009	Mammary intraepithelial neoplasia outgrowths (MINO): MINO and human ductal carcinoma in situ. 2003 , 5, 1	3
2008	Preneoplasia in mouse models. 2003 , 5, 1	78
2007	Advanced imaging and detection R&D in the Center for Biophotonics. 2003 , 5, 1	78
2006	Ultrasound imaging of tumor perfusion. 2003 , 5, 1	78
2005	Imaging angiogenesis in early stages of breast cancer using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. 2003 , 5, 1	78
2004	Imaging mouse models of breast cancer with positron emission tomography. 2003 , 5, 1	78
2003	A hybrid functional/anatomical imaging system for high-throughput planar projection mouse imaging. 2003 , 5, 1	78
2002	Using genomic similarities and differences to interpret mouse models of human development and cancer. 2003 , 5, 1	78
2001	Germline mutations in DNA repair and cell cycle checkpoint genes: consequential somatic gene alterations and genome instability. 2003 , 5, 1	2
2000	Expression profiling of breast cancer, influence of tumor genotype and patient genotype. 2003 , 5, 1	78
1999	Function of LEF1 in early mammary development. 2003 , 5, 1	78
1998	Hormonal interactions during mammary gland development. 2003 , 5, 1	2
1997	Transforming growth factor β role in mammary gland development and carcinogenesis. 2003 , 5, 1	2
1996	Genetic determinants of susceptibility to estrogen-induced mammary cancer in the rat. 2003 , 5, 1	78
1995	Role of differentiation in carcinogenesis and cancer prevention. 2003 , 5, 1	8

1994	Genetically engineered mouse models of human breast cancer. 2003 , 5, 1	3
1993	Modeling breast cancer in the rat: a method to produce knockout rats. 2003 , 5, 1	78
1992	The mouse in preclinical trials: transgenic, carcinogen-induced, or xenograph models â which to use?. 2003 , 5, 1	3
1991	Synergy between the erbB and transforming growth factor beta signaling networks: implications for molecular therapeutics in human neoplasia. 2003 , 5, 1	78
1990	Proof-of-concept in vivo evaluation of targeted therapeutics: lessons from immunoliposomes. 2003 , 5, 1	78
1989	The comparative genetics and genomics of cancer: of mice and men. 2003 , 5, 1	78
1988	The molecular biology of mammary intraepithelial neoplasia outgrowths. 2003 , 5, 1	4
1987	Predicting breast cancer behavior by microarray analysis. 2003 , 5, 1	4
1986	The ErbB receptor tyrosine kinases and their roles in cancer. 2003 , 5, 1	78
1985	Steroid regulation of breast cancer cell proliferation. 2003 , 5, 1	78
1984	Pregnancy levels of estrogen prevents breast cancer. 2003 , 5, 1	0
1983	Clinical breast cancer and estrogen. 2003 , 5, 1	1
1982	Development of a transgenic mouse line for the evaluation of the androgen receptor activity in vivo. 2003 , 5, 1	78
1981	Use of mouse models to validate and therapeutically target transforming growth factor beta as an important player in breast cancer progression. 2003 , 5, 1	78
1980	Role of animal models in oncology drug discovery. 2003 , 5, 1	78
1979	Herceptin-sensitivity of HER2-transgenic mouse mammary tumors. 2003 , 5, 1	1
1978	Genetically modified cancer models: the value of luciferase-tagged tumors and in vivo luciferase-based reporter assays in oncology drug discovery. 2003 , 5, 1	3
1977	Positron emission tomography and X-ray computed tomography: tools for mouse phenotyping?. 2003 , 5, 1	78

1976	Mammary pathology of the genetically engineered mouse. 2003 , 5, 1	78
1975	Whole Slide Imaging and telepathology. 2003 , 5, 1	78
1974	Advanced immunophenotyping: more is better!. 2003 , 5, 1	78
1973	Genetically altered mice and cancer research: effects of the other 99.999% of the genome and other variables upon phenotype. 2003 , 5, 1	2
1972	The Mutant Mouse Regional Resource Center Program. 2003 , 5, 1	1
1971	Genetic manipulation of the mammary gland by transplantation. 2003 , 5, 1	78
1970	Reversibility and progression in conditional transgenic mouse models of breast cancer. 2003 , 5, 1	1
1969	Integrin-mediated signal transduction in transgenic mouse models of human breast cancer. 2003 , 5, 1	1
1968	Mouse models for BRCA1-associated breast cancer. 2003 , 5, 1	78
1967	Estrogen receptor alpha-positive and negative mouse mammary tumors through somatic mutations of p53 in mammary carcinogenesis. 2003 , 5, 1	78
1966	Mouse models of human breast cancer: evolution or convolution?. 2003 , 5, 1	28
1965	Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray. 2003 , 4, R9	277
1964	Looking beyond morphology: cancer gene expression profiling using DNA microarrays. 2003 , 21, 937-49	38
1963	.	1
1962	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10393-8	11.5 1562
1961	Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. 2003 , 144, 4562-74	806
1960	Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. 2003 , 21, 740-53	51
1959	Use of a three-color cDNA microarray platform to measure and control support-bound probe for improved data quality and reproducibility. 2003 , 31, e60	41

1958	Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. 2003 , 2, 242-7		51
1957	Variation in gene expression patterns in human gastric cancers. 2003 , 14, 3208-15		253
1956	Variation in gene expression patterns in follicular lymphoma and the response to rituximab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 1926-30	11.5	128
1955	Systemic and cell type-specific gene expression patterns in scleroderma skin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 12319-24	11.5	334
1954	Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 15853-8	11.5	451
1953	Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. 2003 , 12, 3245-58		39
1952	A neural survival factor is a candidate oncogene in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10931-6	11.5	100
1951	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 11606-11	11.5	1295
1950	Salivary gland-like tumours of the breast: surgical and molecular pathology. 2003 , 56, 497-506		139
1949	Introduction to Classification in Microarray Experiments. 2003 , 132-149		3
1948	Applications of array technology: identification of molecular targets in bladder cancer. 2003 , 89, 2172-7		46
1947	Microarray analysis using amplified mRNA from laser capture microdissection of microscopic hepatocellular precancerous lesions and frozen hepatocellular carcinomas reveals unique and consistent gene expression profiles. 2003 , 31, 295-303		21
1946	Transcriptional regulation and signature patterns revealed by microarray analyses of <i>Streptococcus pneumoniae</i> R6 challenged with sublethal concentrations of translation inhibitors. 2003 , 185, 359-70		112
1945	Genetic variations in peripheral blood mononuclear cells in piglets used as an animal model for staphylococcal enterotoxin exposures. 2003 , 7, 401-9		5
1944	Gene expression patterns in ovarian carcinomas. 2003 , 14, 4376-86		273
1943	The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. 2003 , 10, 193-202		124
1942	Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 9608-13	11.5	166
1941	Expression deconvolution: a reinterpretation of DNA microarray data reveals dynamic changes in cell populations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10370-5	11.5	104

1940	Three color cDNA microarrays: quantitative assessment through the use of fluorescein-labeled probes. 2003 , 31, e14	48
1939	Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. 2003 , 21, 3469-78	387
1938	HIN-1 and the nosology of breast cancer. 2003 , 2, 564-5	1
1937	New insights into estrogen receptor function in human breast cancer. 2003 , 35, 614-31	41
1936	Gene expression phenotypes of Arabidopsis associated with sensitivity to low temperatures. 2003 , 132, 893-906	120
1935	SEP: score for expression profile-a novel method for predicting clinical outcome in breast cancer.	1
1934	DNA microarrays and development. 2003 , 12 Spec No 1, R1-8	39
1933	Gene expression in cancer: the application of microarrays. 2003 , 3, 185-200	35
1932	Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. 2003 , 11, 1-8	78
1931	DNA microarray and cancer. 2003 , 15, 36-43	44
1930	Molecular classification of breast carcinomas using tissue microarrays. 2003 , 12, 27-34	142
1929	Gene expression profiling of endocrine tumors by microarray analysis. 2003 , 10, 162-167	
1928	Gene-expression profiles and breast-cancer prognosis. 2003 , 10, 338-46	1
1927	. 2003 , 11, 1-8	26
1926	Clinical trial methods to discover and validate predictive markers for treatment response in cancer. 2003 , 9, 259-67	14
1925	HER-2/neu testing in breast cancer. 2003 , 120 Suppl, S53-71	19
1924	Demystified...tissue microarray technology. 2003 , 56, 198-204	93
1923	Microarrays in Cancer: Research and Applications. 2003 , 34, S4-S15	29

1922 Molecular Characterization of Breast Cancer Aggressiveness. **2003**, 18, 36-39

1921 Genetic Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. **2003**, 18, 54-56 2

1920 Quantitative Real-Time RT-PCR Analysis of Eight Novel Estrogen-Regulated Genes in Breast Cancer. **2003**, 18, 123-129 13

1919 Squamous Carcinomas of the Head and Neck. **2003**, 509-VIII

1918 Applications of microarrays to renal transplantation: progress and possibilities. **2003**, 8, s913-23 9

1917 Application of DNA array analyses in the management of gastrointestinal cancer patients. **2003**, 21, 309-14 4

1916 Statistical Challenges in Functional Genomics. **2003**, 18, 33 67

1915 Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. **2004**, 19, 275-82 22

1914 . **2004**, 4

1913 Expression profiling and breast cancer biology. **2004**, 19, 29-34 1

1912 Fishing in the bloodstream: insights into the mechanisms of pulmonary hypertension?. **2004**, 170, 827-8 6

1911 Microarray analysis of human nervous system gene expression in neurological disease. **2004**, 60, 135-51 1

1910 Adjustment of systematic microarray data biases. **2004**, 20, 105-14 313

1909 New stars in the sky of treatment for early breast cancer. **2004**, 350, 1140-2 19

1908 Classification of cDNA array genes that have a highly significant discriminative power due to their unique distribution in four brain regions. **2004**, 23, 661-74 4

1907 Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. **2004**, 18, 402-11 113

1906 Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9309-14 11,5 790

1905 Prophylactic oophorectomy and hormone replacement therapy: protection at what price?. **2004**, 22, 978-80 17

1904	Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. 2004 , 10, 6418-31	53
1903	Similarity of mRNA phenotypes of morphologically normal macular and peripheral retinal pigment epithelial cells in older human eyes. 2004 , 45, 3291-301	37
1902	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. 2004 , 10, 6622-8	293
1901	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. 2004 , 10, 6143-51	175
1900	Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. 2004 , 64, 3525-32	103
1899	Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. 2004 , 10, 2368-78	45
1898	Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. 2004 , 32, e74	152
1897	DNA amplification method tolerant to sample degradation. 2004 , 14, 2357-66	73
1896	Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. 2004 , 15, 2523-36	488
1895	Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. 2004 , 10, 155-65	73
1894	Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r. 2004 , 3, 43-55	59
1893	Lessons from genetic profiling in soft tissue sarcomas. 2004 , 75, 35-50	8
1892	Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. 2004 , 10, 8204-13	76
1891	The promise of molecular profiling for cancer identification and treatment. 2004 , 2, 147-50	13
1890	Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. 2004 , 64, 3807-13	284
1889	Controversies in the adjuvant treatment of breast cancer: the role of taxanes. 2004 , 15 Suppl 4, iv17-21	2
1888	Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. 2004 , 64, 3037-45	208
1887	Intracellular patterns of Her-2/neu, ras, and ploidy abnormalities in primary human breast cancers predict postoperative clinical disease-free survival. 2004 , 10, 3042-52	11

1886	A molecular signature of the Nottingham prognostic index in breast cancer. 2004 , 64, 2962-8		55
1885	Cell-type-specific responses to chemotherapeutics in breast cancer. 2004 , 64, 4218-26		307
1884	Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. 2004 , 10, 2272-83		58
1883	Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. 2004 , 10, 5988-97		121
1882	Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. 2004 , 10, 4971-82		84
1881	Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation. 2004 , 57, 1278-87		4
1880	BRCA1 functions as a breast stem cell regulator. 2004 , 41, 1-5		122
1879	Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 8431-6	11.5	174
1878	Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. 2004 , 10, 7500-10		140
1877	Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. 2004 , 64, 3907-13		57
1876	MYC is amplified in BRCA1-associated breast cancers. 2004 , 10, 499-507		71
1875	Application of gene expression profiling for validating models of human breast cancer. 2004 , 32 Suppl 1, 84-9		4
1874	Protein kinase C alpha expression in breast and ovarian cancer. 2004 , 67, 1-10		66
1873	Basal and luminal breast cancers: Basic or luminous? (Review). 2004 , 25, 249		4
1872	Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: Tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. 2004 , 25, 1397		
1871	Gene expression profiling identifies matrilysin overexpression in malignant mesothelioma. 2004 , 125, 1843-52		84
1870	Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. 2004 , 64, 1632-8		78
1869	Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. 2004 , 10, 958-63		36

1868	Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. 2004 , 10, 5508-17	98
1867	The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 4158-63	11.5 267
1866	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. 2004 , 64, 3814-22	136
1865	Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. 2004 , 64, 1522-33	279
1864	Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. 2004 , 10, 2776-83	40
1863	Coexpression analysis of human genes across many microarray data sets. 2004 , 14, 1085-94	571
1862	Robust sparse hyperplane classifiers: application to uncertain molecular profiling data. 2004 , 11, 1073-89	24
1861	Differential gene-expression profiles associated with gastric adenoma. 2004 , 90, 216-23	23
1860	Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. 2004 , 2, E7	698
1859	Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. 2004 , 10, 2670-4	107
1858	Impact of microarray technology in clinical oncology. 2004 , 22, 312-20	23
1857	Abstracts BCI Conference 2004. 2004 , 64, 317-441	0
1856	Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. 2004 , 95, 218-25	181
1855	Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. 2004 , 95, 496-502	68
1854	Applications of microarrays to histopathology. 2004 , 44, 97-108	73
1853	Hallmarks of 'BRCAness' in sporadic cancers. 2004 , 4, 814-9	1268
1852	Identification and validation of an ERBB2 gene expression signature in breast cancers. 2004 , 23, 2564-75	101
1851	Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. 2004 , 23, 3737-48	63

1850	Microarray expression profiling in melanoma reveals a BRAF mutation signature. 2004 , 23, 4060-7	159
1849	Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. 2004 , 23, 6199-208	53
1848	Mutation of GATA3 in human breast tumors. 2004 , 23, 7669-78	209
1847	DNA-microarray analysis of brain cancer: molecular classification for therapy. 2004 , 5, 782-92	166
1846	Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. 2004 , 90, 853-9	25
1845	Molecular profiling of breast cancer: clinical implications. 2004 , 90, 1120-4	77
1844	Breast cancer prognosis in relation to family history of breast and ovarian cancer. 2004 , 90, 1378-81	31
1843	Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. 2004 , 90, 1942-8	122
1842	cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. 2004 , 84, 320-31	57
1841	Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. 2004 , 17, 756-64	28
1840	Genomic approaches in cancer biology. 2004 , 136, 511-8	3
1839	Application of microarray profiling to clinical trials in cancer. 2004 , 136, 519-23	13
1838	Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. 2004 , 5, 489-500	516
1837	Therapeutic targeting in the estrogen receptor hormonal pathway. 2004 , 31, 28-38	81
1836	Molecular therapeutics: promise and challenges. 2004 , 31, 39-53	19
1835	ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. 2004 , 92, 31-9	84
1834	Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. 2004 , 93, 292-300	13
1833	Tests for finding complex patterns of differential expression in cancers: towards individualized medicine. 2004 , 5, 110	34

1832	Utilization of a labeled tracking oligonucleotide for visualization and quality control of spotted 70-mer arrays. 2004 , 5, 12	31
1831	Feature extraction and signal processing for nylon DNA microarrays. 2004 , 5, 38	35
1830	Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. 2004 , 5, 94	87
1829	FunnyBase: a systems level functional annotation of Fundulus ESTs for the analysis of gene expression. 2004 , 5, 96	30
1828	Preoperative chemotherapy and endocrine therapy in patients with breast cancer. 2004 , 5, 198-207	5
1827	Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. 2004 , 5, 364-9	12
1826	Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. 2004 , 154, 63-6	47
1825	A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. 2004 , 5, 607-16	774
1824	Molecular characterization of the tumor microenvironment in breast cancer. 2004 , 6, 17-32	1038
1823	Relevance of breast cancer cell lines as models for breast tumours: an update. 2004 , 83, 249-89	602
1822	HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. 2004 , 86, 197-206	50
1821	Application of sector protein microarrays to clinical samples. 2004 , 1, 91-99	4
1820	Breast cancer biomarkers and molecular medicine: part II. 2004 , 4, 169-88	35
1819	Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. 2004 , 90, 1814-24	44
1818	Data-driven computer simulation of human cancer cell. 2004 , 1020, 132-53	76
1817	Les banques de tissus tumoraux appliqu��s au cancer du sein : pourquoi? Comment?. 2004 , 6, 93-98	1
1816	Traitement adjuvant du cancer du sein, aujourd��hui et demain: « Carte » ou « Menu »?. 2004 , 6, 99-106	
1815	Gene expression profiling in breast cancer: from molecular portraits to personalized medicine. 2004 , 6, 192-202	1

1814	Prediction of tumor outcome based on gene expression data. 2004 , 9, 177-182	1
1813	Current progress in the prediction of chemosensitivity for breast cancer. 2004 , 11, 42-8	12
1812	Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy. 2004 , 11, 3S-8S	11
1811	Magnetic resonance imaging contrast-enhanced relaxometry of breast tumors: an MRI multicenter investigation concerning 100 patients. 2004 , 22, 475-81	30
1810	In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression. 2004 , 35, 595-601	9
1809	Biomolecular features of clinical relevance in breast cancer. 2004 , 31 Suppl 1, S3-14	8
1808	The curability of breast cancer and the treatment of advanced disease. 2004 , 31 Suppl 1, S149-61	105
1807	Role of HER2/neu in tumor progression and therapy. 2004 , 61, 2965-78	110
1806	Genchipdiagnostik. 2004 , 37, 203-209	
1805	Expression of luminal and basal cytokeratins in human breast carcinoma. 2004 , 203, 661-71	442
1804	Molecular genetics of late-onset Alzheimer's disease. 2004 , 68, 381-404	133
1803	Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice. 2004 , 129C, 56-64	12
1802	Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. 2004 , 41, 65-79	42
1801	Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. 2004 , 101, 1490-500	103
1800	Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast. 2004 , 31, 207-15	29
1799	Resolution of cellular physiology by genomic expression signature analysis: Bridging the content gap between in vitro and in vivo drug development. 2004 , 62, 119-123	
1798	Translating the Genome into individualized therapeutics. 2004 , 62, 371-382	5
1797	Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. 2004 , 111, 892-9	20

1796	Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. 2004 , 112, 14-25	258
1795	Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. 2004 , 200, 440-50	39
1794	Mapping phenotypic landscapes using DNA micro-arrays. 2004 , 6, 177-85	10
1793	State of the science: molecular classifications of breast cancer for clinical diagnostics. 2004 , 37, 572-8	13
1792	Bioinformatics and cellular signaling. 2004 , 15, 78-81	29
1791	Modeling of SEB-induced host gene expression to correlate in vitro to in vivo responses. 2004 , 20, 719-27	7
1790	Hypermethylation in histologically distinct classes of breast cancer. 2004 , 10, 5998-6005	102
1789	Automatic construction of gene relation networks using text mining and gene expression data. 2004 , 29, 169-83	11
1788	Use of proteomic analysis to monitor responses to biological therapies. 2004 , 4, 83-93	77
1787	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. 2004 , 10, 5367-74	2156
1786	Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. 2004 , 6, 744-50	255
1785	Utility of linearly amplified RNA for RT-PCR detection of chromosomal translocations: validation using the t(2;5)(p23;q35) NPM-ALK chromosomal translocation. 2004 , 6, 16-21	7
1784	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 811-6	11.5 1047
1783	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. 2004 , 64, 830-5	307
1782	E15. Use of micro-array analysis to predict outcome and response in breast cancer patients. 2004 , 2, 49-50	
1781	Identification of a three-gene expression signature of poor-prognosis breast carcinoma. 2004 , 3, 37	25
1780	Methods to find out the expression of activated genes. 2004 , 2, 68	5
1779	Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. 2004 , 350, 1605-16	822

1778	CNS metastases in breast cancer. 2004 , 22, 3608-17	526
1777	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. 2004 , 351, 2817-26	4778
1776	Proteotypic classification of spontaneous and transgenic mammary neoplasms. 2004 , 6, R668-79	22
1775	Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?. 2004 , 6, 192-200	18
1774	Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004. 2004 , 6, 148-52	1
1773	Prognostic molecular markers in early breast cancer. 2004 , 6, 109-18	156
1772	Multistep tumorigenesis and the microenvironment. 2004 , 6, 93-101	74
1771	Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. 2004 , 6, R46-55	35
1770	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. 2004 , 5, R66	213
1769	Molecular tumor profiling: translating genomic insights into clinical advances. 2004 , 5, 113	2
1768	Population genetic variation in gene expression is associated with phenotypic variation in <i>Saccharomyces cerevisiae</i> . 2004 , 5, R26	159
1767	ONCOMINE: a cancer microarray database and integrated data-mining platform. 2004 , 6, 1-6	2548
1766	Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. 2004 , 111, 162-74	21
1765	Reversibility of oncogene-induced cancer. 2004 , 14, 37-42	63
1764	Prediction of hormone sensitivity by DNA microarray. 2004 , 58, 1-9	22
1763	A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. 2004 , 209, 231-6	19
1762	Customizing chemotherapy for colon cancer: the potential of gene expression profiling. 2004 , 7, 209-18	14
1761	The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. 2004 , 40, 342-51	127

1760	Genomic and proteomic technologies for individualisation and improvement of cancer treatment. 2004 , 40, 2623-32	77
1759	Understanding cancer at the chromosome level: 40 years of progress. 2004 , 40, 1960-7	6
1758	Gene expression microarray technologies in the development of new therapeutic agents. 2004 , 40, 2560-91	70
1757	Transcription profiling of gene expression in drug discovery and development: the NCI experience. 2004 , 40, 2544-9	23
1756	Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. 2004 , 40, 2667-75	267
1755	Breast cancer, stem/progenitor cells and the estrogen receptor. 2004 , 15, 193-7	258
1754	[What place for DNA microarray in inflammatory diseases?]. 2004 , 25, 732-9	8
1753	Multi-platform, multi-site, microarray-based human tumor classification. 2004 , 164, 9-16	178
1752	Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. 2004 , 164, 35-42	469
1751	Molecular classification of parathyroid neoplasia by gene expression profiling. 2004 , 165, 565-76	33
1750	Time-dependent changes in transcriptional profiles within five rat brain regions in response to nicotine treatment. 2004 , 132, 168-80	58
1749	Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. 2004 , 10, 113-8	48
1748	About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. 2004 , 219, 1-7	114
1747	Prediction of lymph node metastasis and perineural invasion of biliary tract cancer by selected features from cDNA array data. 2004 , 122, 184-94	25
1746	Micro arrays and the need for chemotherapy. 2004 , 2, 158-159	
1745	Pharmacogenetics and genomics âprognostication and prediction: where is the future?. 2004 , 2, 159	
1744	Combining proteomics and genomics for cancer analysis. 2004 , 2, 159	
1743	Cognitive functions after chemotherapy. 2004 , 2, 159	

1742 Surgery. **2004**, 2, 159-160

1741 Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. **2004**, 9, 361-77 150

1740 HER-2/neu evaluation in breast cancer are we there yet?. **2004**, 121 Suppl, S33-49 19

1739 Genomic and proteomic approaches for probing the role of vitamin D in health. **2004**, 80, 1730S-4S 10

1738 Expression genomics and cancer biology. **2004**, 5, 1117-28 4

1737 Challenges in breast cancer clinical trial design in the postgenomic era. **2004**, 16, 536-41 13

1736 Bibliography. Current world literature. Endocrine tumors. **2004**, 16, 50-9

1735 Pharmacogenomics. **2004**, 11, 211-20 32

1734 Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. **2004**, 64, 64-71 166

1733 Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. **2004**, 103, 2727-37 104

1732 Application of proteomics in the study of tumor metastasis. **2004**, 2, 152-66 22

1731 High expression of two genes selected by iAFLP: A new prognostic factor of estrogen receptor-positive breast cancer. **2004**, 12, 381 1

1730 Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma. **2004**, 12, 287 2

1729 Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. **2004**, 1, 134-40 49

1728 The pathology of hereditary breast cancer. **2004**, 2, 131-8 16

1727 Bayesian Methods for DNA Microarray Data Analysis. **2005**, 713-742 6

1726 Associating Microarray Data with a Survival Endpoint. **2005**, 109-120

1725 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. **2005**, 28, 79-119 27

1724	Quantitative in'situ cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis. 2005 , 2, 291-300	2
1723	Clinical application of molecular profiling in breast cancer. 2005 , 1, 485-96	11
1722	Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. 2005 , 70, 93-7	18
1721	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. 2005 , 29, 633-9	206
1720	Systems Biology: Applications in Drug Discovery. 2005 , 123-183	14
1719	Genomics-based prognosis and therapeutic prediction in breast cancer. 2005 , 3, 291-300	47
1718	Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. 2005 , 12, 10-9	106
1717	Origins and evolution of cell phenotypes in breast tumors. 2005 , 233, 43-54	8
1716	The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. 2005 , 201, 713-25	93
1715	In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053). 2005 , 63, 1275-6	2
1714	cRNA target preparation for microarrays: comparison of gene expression profiles generated with different amplification procedures. 2005 , 344, 92-101	24
1713	Protein microarrays as tools for functional proteomics. 2005 , 9, 14-9	231
1712	The pathology of breast cancer and the role of the histopathology laboratory. 2005 , 17, 234-9	11
1711	Gene expression arrays in cancer research: methods and applications. 2005 , 54, 95-105	63
1710	Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. 2005 , 12, 166-77	7
1709	Geometric representation of high dimension, low sample size data. 2005 , 67, 427-444	254
1708	p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. 2005 , 47, 458-66	77
1707	Isolation and characterization of human mammary stem cells. 2005 , 38, 375-86	64

1706	Genomic approaches in the management and treatment of breast cancer. 2005 , 92, 618-24	26
1705	Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. 2005 , 92, 1561-73	94
1704	Histopathologic indicators of breast cancer biology: insights from population mammographic screening. 2005 , 92, 1366-71	12
1703	Natural variation in cardiac metabolism and gene expression in <i>Fundulus heteroclitus</i> . 2005 , 37, 67-72	159
1702	A streamlined platform for high-content functional proteomics of primary human specimens. 2005 , 2, 691-7	212
1701	The promise of genetically engineered mice for cancer prevention studies. 2005 , 5, 184-98	57
1700	Breast cancer metastasis: markers and models. 2005 , 5, 591-602	1591
1699	Biomarkers in cancer staging, prognosis and treatment selection. 2005 , 5, 845-56	1278
1698	Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. 2005 , 24, 963-73	131
1697	Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. 2005 , 24, 2705-14	70
1696	Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. 2005 , 24, 3177-86	53
1695	Identification of molecular apocrine breast tumours by microarray analysis. 2005 , 24, 4660-71	594
1694	Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. 2005 , 24, 6646-56	315
1693	A quantitative genomic expression analysis platform for multiplexed in vitro prediction of drug action. 2005 , 5, 126-34	17
1692	Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. 2005 , 85, 1040-50	177
1691	Clinical application of array-based comparative genomic hybridization to define the relationship between multiple synchronous tumors. 2005 , 18, 591-7	22
1690	Predominance of high-grade pathway in breast cancer development of Middle East women. 2005 , 18, 891-7	51
1689	Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. 2005 , 18, 1165-75	57

1688	Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. 2005 , 18, 1321-8	153
1687	Stem cell biology and the cellular pathways of carcinogenesis. 2005 , 113, 922-9	38
1686	Characterization of gene expression in major types of salivary gland carcinomas with epithelial differentiation. 2005 , 156, 104-13	29
1685	A conditional feedback loop regulates Ras activity through EphA2. 2005 , 8, 111-8	190
1684	The transcriptional repressor Snail promotes mammary tumor recurrence. 2005 , 8, 197-209	585
1683	Oh what a tangled web it weaves: BRCA1 and DNA decatenation. 2005 , 8, 95-7	8
1682	Metastasis gets site specific. 2005 , 8, 93-5	35
1681	GATA-3 expression as a predictor of hormone response in breast cancer. 2005 , 200, 705-10	55
1680	Adjuvant chemotherapy for breast cancer--"one fits all"? 2005 , 14, 564-9	7
1679	Prognostic and predictive factors revisited. 2005 , 14, 493-9	85
1678	GenSo-FDSS: a neural-fuzzy decision support system for pediatric ALL cancer subtype identification using gene expression data. 2005 , 33, 61-88	45
1677	Accumulation of ubiquitin-conjugated cytokeratin fragments in tumor cells. 2005 , 15, 309-18	8
1676	Cyclin E as a prognostic and predictive marker in breast cancer. 2005 , 15, 319-26	51
1675	Bringing molecular prognosis and prediction to the clinic. 2005 , 6, 61-76	30
1674	Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. 2005 , 6, 315-24	6
1673	Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. 2005 , 5, 45	113
1672	A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. 2005 , 5, 93	18
1671	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. 2005 , 96, 684-94	93

1670	ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers. 2005 , 42, 204-5; author reply 206	7
1669	Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury. 2005 , 42, 1137-47	25
1668	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. 2005 , 116, 340-50	443
1667	Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. 2005 , 117, 934-41	14
1666	Women age 2005, 103, 2466-72	63
1665	References. 2005 , 152-182	
1664	Follicular thyroid lesions, elements that affect both diagnosis and prognosis. 2005 , 89, 108-13	36
1663	Estrogen signaling and prediction of endocrine therapy. 2005 , 56 Suppl 1, 27-31	12
1662	Adaptor-tagged competitive polymerase chain reaction: amplification bias and quantified gene expression levels. 2005 , 339, 15-28	7
1661	p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. 2005 , 447, 688-94	177
1660	Gene expression profiling of primary breast cancer. 2005 , 7, 38-44	15
1659	Stem/progenitor cells in mouse mammary gland development and breast cancer. 2005 , 10, 17-24	64
1658	Epithelial progenitors in the normal human mammary gland. 2005 , 10, 49-59	131
1657	Maintenance of cell type diversification in the human breast. 2005 , 10, 61-74	13
1656	Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. 2005 , 10, 211-9	30
1655	Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. 2005 , 10, 249-60	96
1654	Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. 2005 , 10, 261-72	188
1653	Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation. 2005 , 10, 273-80	21

1652	BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. 2005 , 91, 179-86	143
1651	Gene profiling in squamous cell carcinoma of the head and neck. 2005 , 24, 87-94	21
1650	The current understanding of the molecular determinants of inflammatory breast cancer metastasis. 2005 , 22, 615-20	14
1649	A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. 2005 , 5, 22	87
1648	Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. 2005 , 205, 359-76	144
1647	Molecular evolution of breast cancer. 2005 , 205, 248-54	391
1646	First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. 2005 , 206, 366-76	80
1645	TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas. 2005 , 207, 14-9	7
1644	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. 2005 , 207, 260-8	172
1643	A multiple testing procedure to associate gene expression levels with survival. 2005 , 24, 3077-88	23
1642	Clinical applications of microarray-based diagnostic tests. 2005 , 39, S577-82	16
1641	Can animal models help us select specific compounds for cancer prevention trials?. 2005 , 166, 71-87	9
1640	DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. 2005 , 241, 16-26	29
1639	Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. 2005 , 77-100	1
1638	. 2005 ,	
1637	Gene Expression Data and Survival Analysis. 2005 , 21-34	2
1636	An integrated approach for tailored treatment in breast cancer. 2005 , 16 Suppl 2, ii203-8	4
1635	DNA microarrays in clinical cancer research. 2005 , 5, 111-20	42

1634	Gene profile and response to treatment. 2005 , 16 Suppl 2, ii195-202	11
1633	Expression genomics and drug development: towards predictive pharmacology. 2005 , 3, 303-21	7
1632	Squamous cell carcinoma of the breast. 2005 , 23, 7827-35	127
1631	From traditional biomarkers to transcriptome analysis in drug development. 2005 , 5, 29-38	34
1630	Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. 2005 , 5, 83-102	31
1629	The Role of DNA-Microarray in Translational Cancer Research. 2005 , 3, 201-216	1
1628	Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. 2005 , 23, 7265-77	461
1627	Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. 2005 , 23, 7278-85	47
1626	Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. 2005 , 11, 8623-31	173
1625	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. 2005 , 65, 4059-66	212
1624	Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. 2005 , 11, 6872-9	42
1623	Genomics and proteomics--the way forward. 2005 , 16 Suppl 2, ii30-44	19
1622	A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. 2005 , 14, 1108-12	159
1621	Testing chemotherapy for breast cancer: timing is everything. 2005 , 23, 5434-6	8
1620	Gene expression profiling of breast cancer: a new tumor marker. 2005 , 23, 1631-5	126
1619	The gene expression signatures of melanoma progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 6092-7	11.5 348
1618	Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. 2005 , 58, 1046-50	31
1617	Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. 2005 , 65, 10208-13	22

1616	Tumor markers in breast cancer- European Group on Tumor Markers recommendations. 2005 , 26, 281-93	246
1615	Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. 2005 , 23, 41-8	292
1614	Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. 2005 , 21, 4205-8	316
1613	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. 2005 , 11, 5175-80	511
1612	Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. 2005 , 26, 1343-53	91
1611	Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. 2005 , 90, 1819-29	204
1610	Microarrays: applications and pitfalls. 2005 , 62, 1669-72	23
1609	Screening of tissue microarrays for ubiquitin proteasome system components in tumors. 2005 , 399, 334-55	5
1608	Breast cancer gene expression profiling: clinical trial and practice implications. 2005 , 6, 49-58	10
1607	Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer. 2005 , 353, 617-22	2
1606	Prognostic relevance of basal cytokeratin expression in operable breast cancer. 2005 , 69, 478-85	83
1605	Validation and quality control of protein microarray-based analytical methods. 2005 , 114, 233-55	5
1604	Modern approaches to age-old questions about thyroid tumors. 2005 , 15, 575-82	7
1603	Differential coexpression analysis using microarray data and its application to human cancer. 2005 , 21, 4348-55	201
1602	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. 2005 , 5, 1069-83	44
1601	Gene Expression Data for DLBCL Cancer Survival Prediction with A Combination of Machine Learning Technologies. 2005 , 2006, 894-7	2
1600	Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. 2005 , 2, 598-9	10
1599	Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. 2005 , 23, 9304-11	311

1598	Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. 2005 , 65, 6864-73	35
1597	Limits of predictive models using microarray data for breast cancer clinical treatment outcome. 2005 , 97, 927-30	104
1596	Ovarian suppression for breast cancer: an effective treatment in search of a home. 2005 , 23, 5869-72	7
1595	Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. 2005 , 280, 12935-43	35
1594	Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. 2005 , 11, 4357-64	69
1593	Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia. 2005 , 42, 735-52	14
1592	Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. 2005 , 65, 2170-8	186
1591	Prediction of radiation sensitivity using a gene expression classifier. 2005 , 65, 7169-76	155
1590	Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3738-43	11.5 823
1589	High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. 2005 , 65, 8530-7	605
1588	Gene expression profiling of chemically induced rat mammary gland cancer. 2005 , 26, 503-9	21
1587	Gene expression profiling in acute myeloid leukemia. 2005 , 23, 6296-305	84
1586	The NFkappaB pathway and endocrine-resistant breast cancer. 2005 , 12 Suppl 1, S37-46	130
1585	An Introduction to MAMA (Meta-Analysis of MicroArray data) System. 2005 , 2005, 7730-3	4
1584	Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. 2005 , 23, 732-40	283
1583	A molecular signature in superficial bladder carcinoma predicts clinical outcome. 2005 , 11, 4029-36	123
1582	Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. 2005 , 3, 203-18	68
1581	Breast cancer molecular subtypes respond differently to preoperative chemotherapy. 2005 , 11, 5678-85	1415

1580	Bladder cancer outcome and subtype classification by gene expression. 2005 , 11, 4044-55	266
1579	Molecular basis of therapeutic strategies for breast cancer. 2005 , 5, 379-96	21
1578	DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy. 2005 , 3, 289-304	8
1577	Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. 2005 , 22, 213-26	67
1576	Aromatase inhibition: translation into a successful therapeutic approach. 2005 , 11, 2809-21	99
1575	Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. 2005 , 65, 1376-83	58
1574	How to best classify breast cancer: Conventional and novel classifications (Review). 2005 , 27, 1307	3
1573	Time-dependent RNA degradation affecting cDNA array quality in spontaneous canine tumours sampled using standard surgical procedures. 2005 , 16, 979	
1572	Classification of Microarray Gene Expression Data Using a New Binary Support Vector System.	2
1571	Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. 2005 , 365, 671-9	2172
1570	Gene-expression profiling in breast cancer. 2005 , 365, 634-5	31
1569	Identification of transcriptional targets of HOXA5. 2005 , 280, 19373-80	39
1568	In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. 2005 , 113, 903-21	37
1567	Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. 2005 , 6, 107	99
1566	2005 Highlights From: Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy; New York, NY September 2005. 2005 , 6, 288-291	
1565	Gene Array Technologies in Biological Investigations. 2005 , 93, 737-749	2
1564	Bioinformatics in otolaryngology. 2005 , 38, 321-32, vii	1
1563	Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. 2005 , 23, 7350-60	696

1562	Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. 2005 , 65, 5991-5; discussion 5995	507
1561	Beyond lymph node staging: molecular predictors of outcome in breast cancer. 2005 , 14, 69-84, vi	1
1560	Microarrays in Clinical Diagnostics. 2005 ,	1
1559	Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors. 2005 , 12, 534-44	24
1558	Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. 2005 , 65, 9155-8	264
1557	Pathology of the Future: Molecular Profiling for Targeted Therapy. 2005 , 23, 36-46	58
1556	Environmental health research in the post-genome era: new fields, new challenges, and new opportunities. 2005 , 8, 71-94	2
1555	Mining the tumor phosphoproteome for cancer markers. 2005 , 11, 3163-9	74
1554	Analysis of SNP-expression association matrices. 2005 , 135-43	2
1553	Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. 2005 , 2, 246-54	77
1552	Cancer diagnostics: decision criteria for marker utilization in the clinic. 2005 , 5, 357-64	22
1551	Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. 2005 , 4, 674-89	31
1550	Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data. 2005 , 21, 3001-8	321
1549	25 Years of p53 Research. 2005 ,	12
1548	Outcome signature genes in breast cancer: is there a unique set?. 2005 , 21, 171-8	622
1547	Advances in Targeted Cancer Therapy. 2005 ,	
1546	ArrayVigil: a methodology for statistical comparison of gene signatures using segregated-one-tailed (SOT) Wilcoxon's signed-rank test. 2005 , 345, 645-9	7
1545	Aromatase inhibitors--socio-economical issues. 2005 , 95, 137-42	3

1544	Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. 2005 , 95, 105-11	15
1543	Partial least squares dimension reduction for microarray gene expression data with a censored response. 2005 , 193, 119-37	13
1542	Logical networks inferred from highly specific discovery of transcriptionally regulated genes predict protein states in cultured gliomas. 2005 , 336, 1278-84	7
1541	Fulvestrant--ready to start its journey in the breast cancer adjuvant endocrine world?. 2005 , 41, 341-3	3
1540	Molecular markers of prostate cancer outcome. 2005 , 41, 858-87	153
1539	Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 2005 , 166, 1205-16	41
1538	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. 2005 , 86, 127-41	218
1537	[Molecular alterations in breast cancer: clinical implications and new analytical tools]. 2005 , 26, 470-8	3
1536	Pathology of Invasive Breast Cancer. 2005 , 98-110	
1535	Multimodality Treatment of Breast Cancer. 2005 , 355-382	
1534	Discovering causes and cures for cancer from gene expression analysis. 2005 , 4, 548-63	11
1533	Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. 2005 , 3, 32	39
1532	Utility of microarrays in the management of breast cancer patients. 2005 , 2, 307-311	
1531	Towards a therapeutic breast cancer vaccine: the next steps. 2005 , 4, 831-41	3
1530	Molecular prediction of tamoxifen resistance in breast cancer. 2005 , 7, 1	78
1529	Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. 2005 , 12, 903-16	65
1528	The promise of gene signatures in cancer diagnosis and prognosis. 2005 ,	
1527	Genomics in breast cancer-therapeutic implications. 2005 , 2, 26-33	41

1526	Breast cancer biomarkers. 2005 , 40, 99-125	17
1525	Molecular Biology of Human Cancers. 2005 ,	4
1524	Molecular mechanisms in gliomagenesis. 2005 , 94, 1-27	55
1523	HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. 2005 , 7, R1058-79	42
1522	Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. 2005 , 7, R634-44	93
1521	Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. 2005 , 7, 143-8	191
1520	The promise of microarrays in the management and treatment of breast cancer. 2005 , 7, 100-4	20
1519	Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. 2005 , 7, 96-9	22
1518	Genomic analysis of human breast cancer in families and populations. 2005 , 7, 1	78
1517	Dynamic imaging of plasticity and escape in tumor cell invasion. 2005 , 7, 1	78
1516	Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA. 2005 , 7, 1	78
1515	Hypoxia promotes invasion and metastasis of breast cancer cells by increasing lysyl oxidase expression. 2005 , 7, 1	1
1514	Brn-3b transcription factor in breast tumourigenesis: regulation of genes associated with growth and migration of cancer cells. 2005 , 7, 1	78
1513	Mammary development fate and breast cancer risk. 2005 , 7, 1	78
1512	Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. 2005 , 7, 1	1
1511	Real-time PCR-based expression profiling of BRCA1-induced genes in primary breast tumors. 2005 , 7, 1	78
1510	Breast tumors induced by high-dose radiation display similar genetic profiles. 2005 , 7, 1	78
1509	Stromal and epithelial TGF- β signaling in mammary tumorigenesis. 2005 , 7, 1	78

1508	The extracellular matrix composition and responsiveness to breast carcinoma therapy. 2005 , 7, 1	78
1507	Determining the factors affecting breast cancer infectivity by oncolytic adenovirus. 2005 , 7, 1	78
1506	HER2 and ER α downregulate estrogen-responsive element-mediated transcription activity of ER β -positive cells in response to estrogen stimulation. 2005 , 7, 1	1
1505	Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion. 2005 , 7, 1	2
1504	Functional genomic approaches to breast cancer. 2005 , 7, 1	78
1503	Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. 2005 , 7, 1	3
1502	Potential mechanisms whereby estrogens induce breast cancer in women. 2005 , 7, 1	1
1501	Potentiated phospho-protein networks in cancer cells. 2005 , 7, 1	1
1500	Identification of molecular apocrine breast tumours by microarray analysis. 2005 , 7, 1	8
1499	Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland. 2005 , 7, 1	78
1498	Comparison of the expression profile in breast cancer and ovarian cancer. 2005 , 7, 1	1
1497	Targeting estrogen to kill ER-positive and ER-negative breast cancer. 2005 , 7, 1	78
1496	High-throughput experimental verification of predicted tissue-specific and tumor-specific splice isoforms. 2005 , 7, 1	78
1495	The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. 2005 , 7, 1	0
1494	Cigarette smoking and breast cancer risk among non-drinking women. 2005 , 7, 1	78
1493	Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer. 2005 , 7, 1	78
1492	Genome-wide expression profiling of microdissected human breast tumor cells: tumor classification predictive of metastases and clinical outcome. 2005 , 7, 1	78
1491	Gene expression profiling in breast cancer challenges the existence of intermediate histological grade. 2005 , 7, 1	78

1490	Molecular approaches to understanding pregnancy-induced protection against breast cancer. 2005 , 7, 1	78
1489	Cooperation between extracellular signaling and intracellular Ras activation leads to immortalization and epithelial-to-mesenchymal transition of variant human mammary epithelial cells. 2005 , 7, 1	78
1488	Immortalization-associated gene signature in breast cancer. 2005 , 7, 1	78
1487	Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. 2005 , 7, 1	78
1486	Identification of differentially expressed genes in canine mammary tumor cell lines using a newly developed canine-specific cDNA microarray. 2005 , 7, 1	78
1485	Genetic and epigenetic changes in early carcinogenesis. 2005 , 7, 1	78
1484	Biological features and xenograft models of a very early human premalignant breast lesion. 2005 , 7, 1	78
1483	Myoepithelial cell layer disruption and human breast cancer invasion. 2005 , 7, 1	1
1482	HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells. 2005 , 7, 1	78
1481	Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. 2005 , 7, 1	78
1480	Chromosomal imbalances mapped by array-based comparative genomic hybridization in an integrated approach to combat breast cancer in Denmark. 2005 , 7, 1	1
1479	DNA copy number changes in breast cancer samples using array-CGH profiling. 2005 , 7, 1	78
1478	Genomic and transcriptional events associated with poor clinical responses to conventional therapies. 2005 , 7, 1	78
1477	Expression profiling of peripheral blood cells for early detection. 2005 , 7, 1	78
1476	HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation. 2005 , 7, 1	78
1475	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. 2005 , 7, 1	78
1474	Mapping the location of recurring amplicons in array-CGH data. 2005 , 7, 1	78
1473	Predicting survival from gene expression data by generalized partial least squares regression. 2005 , 7, 1	2

1472	Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes. 2005 , 7, 1	1
1471	Molecular distinctions among ERBB2-overexpressing breast cancers. 2005 , 7, 1	78
1470	In vitro models for tumor protein d52 function in cancer cells. 2005 , 7, 1	78
1469	Protein expression and gene amplification of primary cyclins (A, B1, D1, D3and E) and secondary cyclins (C and H) in relation to prognosis in breast cancer patients. 2005 , 7, 1	0
1468	TP53 mutations among molecular subtypes of HER2-positive tumors. 2005 , 7, 1	78
1467	Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP. 2005 , 7, 1	78
1466	Targeting the cell cycle for prognosis and therapy of breast cancer. 2005 , 7, 1	78
1465	Expression profiling as a prognostic and predictive factor in breast cancer. 2005 , 7, 1	78
1464	Lack of evidence for nuclear IGFBP5 in mammary epithelial cells. 2005 , 7, 1	78
1463	Expression of wild-type and mutated TP53in breast carcinomas. 2005 , 7, 1	78
1462	Cancer gene mutation discovery and detection using array-based resequencing. 2005 , 7, 1	78
1461	The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. 2005 , 7, 1	78
1460	High-resolution representational oligonucleotide microarray analysis and fluorescence in situ hybridization analysis of aneuploid and diploid breast tumors. 2005 , 7, 1	78
1459	A single nucleotide polymorphism in the HDM-2 gene regulates the p53 apoptotic response and influences the age of onset of cancers in humans: the SNP 309 HDM-2 polymorphism. 2005 , 7, 1	78
1458	Microcell-mediated transfer of chromosome 6 into the breast cancer cell line MDA-MB-231: a specific set of genes is involved in the reversion of the tumorigenic phenotype. 2005 , 7, 1	78
1457	Prognostic value genotypes and LOH at TP53 codon 72 and TP53mutations in primary breast cancer. 2005 , 7, 1	78
1456	Detection of minimal disease in breast cancer. 2005 , 7, 1	78
1455	Association of NCOA3 (AIB1) polymorphisms with breast cancer risk. 2005 , 7, 1	1

1454	A critical need for molecular markers of breast cancer risk and risk reduction. 2005, 7, 1	78
1453	TP53 and additional pathways in therapy resistance. 2005, 7, 1	78
1452	Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer. 2005, 7, 1	78
1451	Development of a rapid screening approach for candidate gene sets in cancer. 2005, 7, 1	78
1450	Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. 2005, 7, 1	78
1449	High-density screening of the Zbtb7 gene in breast cancer patients. 2005, 7, 1	1
1448	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. 2005, 7, 1	78
1447	Role of HER2 in local relapse and metastasis. 2005, 7, 1	78
1446	Development of CDK inhibitors as cancer therapeutics. 2005, 7, 1	1
1445	Expression profiling of Wnt pathway genes in breast cancer. 2005, 7, 1	78
1444	Gene expression studies in radiation-sensitive cell lines. 2005, 7, 1	78
1443	Breast tumors induce the recruitment of AC133+KDR+ endothelial precursor cells mobilized by plasma vascular endothelial growth factor. 2005, 7, 1	2
1442	Identification of drug targets for the treatment of Basal-like tumors. 2005, 7, 1	1
1441	BRCA1 directly modulates gene expression required for estrogen biosynthesis: a possible mechanism of tissue-specific tumor suppression. 2005, 7, 1	78
1440	The search for low-penetrance breast cancer genes. 2005, 7, 1	2
1439	Molecular characterization of breast cell lines: a tool for breast cancer studies. 2005, 7, 1	78
1438	SNPS in putative regulatory loci controlling gene expression in cancer. 2005, 7, 1	78
1437	Characterization of extracellular matrix composition in breast carcinoma. 2005, 7, 1	78

1436	The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling. 2005, 7, 1	78
1435	Proteomic approaches to early detection of breast cancer. 2005, 7, 1	78
1434	Reproducibility of molecular portraits in early stage breast cancer. 2005, 7, 1	78
1433	Gene expression signature of hereditary breast cancer. 2005, 7, 1	78
1432	ATM mutations associated with breast cancer. 2005, 7, 1	78
1431	The future of breast cancer prevention. 2005, 7, 1	78
1430	A model of the BRCA1/BRCA2 network. 2005, 7, 1	78
1429	The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells. 2005, 7, 1	4
1428	Gene expression profiling to identify parity-induced changes in the human mammary gland. 2005, 7, 1	1
1427	Envisioning new targets and new approaches for molecular-based cancer therapeutics. 2005, 7, 1	78
1426	High prevalence of a BRCA1 gene founder mutation, 5083del19, in unselected breast&ovarian cancer patients from Southern Italy: genotype&phenotype correlations. 2005, 7, 1	2
1425	Lymph node metastases display gene expression profiles of their primary breast carcinomas. 2005, 7, 1	78
1424	Comparative expressed sequence hybridisation revealed distinct chromosomal regions of differential gene expression in breast cancer subtypes. 2005, 7, 1	78
1423	ER&in normal and malignant breast. 2005, 7, 1	78
1422	RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments. 2005, 7, 1	1
1421	Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis. 2005, 7, 1	78
1420	Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families. 2005, 7, 1	78
1419	Promoter composition predicts gene classes in microarray expression analyses of breast cancer. 2005, 7, 1	78

1418	Predicting response/resistance to endocrine therapy for breast cancer. 2005 , 7, 1	78
1417	The role of the tumor microenvironment in breast cancer progression. 2005 , 7, 1	78
1416	Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma. 2005 , 7, 1	78
1415	6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells. 2005 , 7, 1	78
1414	Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005 , 7, 1	78
1413	Discovering genetic profiles by array-CGH in familial breast tumors. 2005 , 7, 1	78
1412	A breast cancer progression model: the importance of three-dimensional tissue architecture and metalloproteinases. 2005 , 7, 1	1
1411	Regulation of epithelial cell polarity during carcinogenesis. 2005 , 7, 1	1
1410	Imprint as a reliable diagnostic tool in breast cancer and possible usefulness for research purposes. 2005 , 7, 1	78
1409	Altered signaling in anti-estrogen-resistant human breast cancer cells. 2005 , 7, 1	78
1408	Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005 , 7, 1	78
1407	Morphogenesis of the mammary gland and the role of keratin expression. 2005 , 7, 1	78
1406	Outcome signature genes in breast cancer: is there a unique set?. 2005 , 7, 1	5
1405	Quality control of DNA with on-chip electrophoresis for oligonucleotide-array comparative genomic hybridization. 2005 , 7, 1	78
1404	DNA polymorphisms of several genes and predisposition to breast cancer. 2005 , 7, 1	1
1403	Stem cells in human breast development and cancer. 2005 , 7, 1	78
1402	Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue. 2005 , 7, 1	78
1401	Who gets cancer?. 2005 , 7, 1	78

1400	Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer. 2005 , 7, 1	1
1399	Chromosome-wide pharmacogenetics: localisation and linkage disequilibrium of genes coding for ROS metabolism and signalling. 2005 , 7, 1	78
1398	Insulin-like growth factor regulation of mammary gland development and tumorigenesis. 2005 , 7, 1	78
1397	Tailored therapies based upon tumor subtype biology. 2005 , 7, 1	78
1396	Functional characterization of genes involved in the development of breast cancer. 2005 , 7, 1	78
1395	IL-8 is a novel marker for breast cancer. 2005 , 7, 1	1
1394	Mutant p53 exerts its gain of function through activation of the NF- κ B pathway. 2005 , 7, 1	78
1393	Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection. 2005 , 7, 1	78
1392	Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation. 2005 , 7, 1	78
1391	Apoptotic chemotherapies. 2005 , 7, 1	78
1390	Genomic profiling of breast cancer. 2005 , 7, 1	78
1389	Deletions at the chromosome 3 common eliminated region 1 on 3p21.3 in human breast tumors. 2005 , 7, 1	78
1388	Identification of clinically relevant gene sets and pathways using functional models of breast tumor suppression. 2005 , 7, 1	78
1387	Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients. 2005 , 7, 1	78
1386	Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer. 2005 , 7, 1	78
1385	Alpha-1 antitrypsin genotypes in breast cancer patients. 2005 , 7, 1	2
1384	ZBTB7 HapMap in a worldwide population study. 2005 , 7, 1	1
1383	Evading p53 action during tumor development and therapy. 2005 , 7, 1	78

1382	Epigenetic silencing of tropomyosin alters transforming growth factor beta control of cell invasion and metastasis. 2005 , 7, 1	78
1381	Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients. 2005 , 7, 1	78
1380	Polymorphisms in the CRK gene and their association with breast cancer risk. 2005 , 7, 1	78
1379	Gene expression profiling in whole-blood samples from postmenopausal women exposed to hormone replacement therapy. 2005 , 7, 1	78
1378	Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer. 2005 , 7, 1	78
1377	Methylation profiling of carcinogenesis-associated genes in sporadic breast cancer. 2005 , 7, 1	78
1376	Application of microarray analyses to identify genes involved in radiation-induced fibrosis. 2005 , 7, 1	1
1375	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. 2005 , 7, 1	1
1374	Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays. 2005 , 7, 1	1
1373	DNA damage response pathways in cancer causation and treatment. 2005 , 7, 1	78
1372	Magnetic resonance spectroscopy of breast cancer tissue used for tumor classification and lymph node prediction. 2005 , 7, 1	1
1371	Sex-hormone binding globulin receptor-mediated growth inhibition in breast cancer cells: a proteomics approach. 2005 , 7, 1	78
1370	Hereditary breast cancer â a spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up. 2005 , 7, 1	78
1369	Genes, genomes, and cancer. 2005 , 7, 1	78
1368	Abstract withdrawn. 2005 , 7, 1	78
1367	Abstract withdrawn. 2005 , 7, 1	78
1366	The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use. 2005 , 7, 1	0
1365	Update on HER2-directed therapy. 2005 , 7, 1	1

1364	Methods for gene expression profiling in clinical trials for breast cancer. 2005 , 7, 1	78
1363	L2L: a simple tool for discovering the hidden significance in microarray expression data. 2005 , 6, R81	101
1362	International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'. 2006 , 8, 303	6
1361	GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. 2006 , 8, R64	24
1360	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. 2006 , 8, R66	108
1359	Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. 2006 , 8, R56	103
1358	CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. 2006 , 8, R59	716
1357	Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. 2006 , 8, R58	107
1356	Predicting a local recurrence after breast-conserving therapy by gene expression profiling. 2006 , 8, R62	163
1355	Classification of ductal carcinoma in situ by gene expression profiling. 2006 , 8, R61	128
1354	When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?. 2006 , 8, 302	1
1353	High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. 2006 , 8, 213	11
1352	Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. 2006 , 8, R34	188
1351	Breast cancer prognosis by combinatorial analysis of gene expression data. 2006 , 8, R41	49
1350	Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples. 2006 , 8, R51	14
1349	The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. 2006 , 8, R32	56
1348	Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. 2006 , 8, R23	150
1347	Cancer du sein. 2006 ,	

1346	Neoadjuvant Therapy of Breast Cancer. 2006 , 5, 411-425	1
1345	Breast Cancer and Molecular Medicine. 2006 ,	2
1344	Microarrays: Use in Gene Identification. 2006 ,	
1343	Biomarkers in Breast Cancer. 2006 ,	3
1342	Immunohistochemical and Clinicopathologic Characteristics of Invasive Ductal Carcinoma of Breast With Micropapillary Carcinoma Component. 2006 , 17, 154	
1341	Histopathologic and Metabolic Criteria for Assessment of Treatment Response in Breast Cancer. 2006 , 1, 83-94	
1340	Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. 2006 , 5, 2947-55	32
1339	Profils d'expression g�nrique et Puces � ADN dans le cancer du sein : choix du patient, choix du protocole. 2006 , 267-276	
1338	Molecular biomarkers for cancer detection in blood and bodily fluids. 2006 , 43, 497-560	13
1337	Comparison of Support Vector Machines to Other Classifiers Using Gene Expression Data. 2006 , 35, 241-256	5
1336	Prevention and Treatment of Age-related Diseases. 2006 ,	2
1335	Locoregional therapy of breast cancer: maximizing control, minimizing morbidity. 2006 , 6, 1281-99	1
1334	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. 2006 , 8, 214	25
1333	Proteomics of breast cancer: principles and potential clinical applications. 2006 , 5, 1772-86	58
1332	2005 Curt Stern Award address. Exploring along a crooked path. 2006 , 79, 429-33	1
1331	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. 2006 , 12, 1533-9	282
1330	Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. 2006 , 82, 175-83	96
1329	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. 2006 , 98, 262-72	1485

1328	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. 2006 , 24, 5652-7	824
1327	Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. 2006 , 6, 59	7
1326	High-throughput biology in the postgenomic era. 2006 , 17, 1077-85	10
1325	2â20 Gene-Expression Profiles to Predict Distant Metastasis of Lymph-Node-Negative Primary Breast Cancer. 2006 , 17, 154-155	2
1324	The Basal Phenotype of BRCA1-Related Breast Cancer. 2006 , 17, 22-25	
1323	Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. 2006 , 7, 237-43	32
1322	Heterogeneity of mammary lesions represent molecular differences. 2006 , 6, 275	29
1321	Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. 2006 , 5, 24	556
1320	Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. 2006 , 5, 47	19
1319	A systems approach to clinical oncology: focus on breast cancer. 2006 , 4, 5	37
1318	Identification of prognostic signatures in breast cancer microarray data using Bayesian techniques. 2006 , 3, 367-81	12
1317	Concordance among gene-expression-based predictors for breast cancer. 2006 , 355, 560-9	1071
1316	The genome is now accessible to the endoscopist. 2006 , 64, 27-8	
1315	Gene expression profiling and clinical outcome in breast cancer. 2006 , 10, 429-43	47
1314	Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. 2006 , 24, 1729-44	50
1313	Chemical and biological differentiation of three human breast cancer cell types using time-of-flight secondary ion mass spectrometry. 2006 , 78, 3651-8	64
1312	Microarray analysis and tumor classification. 2006 , 354, 2463-72	363
1311	Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. 2006 , 66, 5278-86	190

1310	Gene expression analysis and clinical diagnosis. 2006 , 363, 157-64	26
1309	Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. 2006 , 126, 489-502	372
1308	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. 2006 , 340, 469-75	52
1307	High-throughput techniques in breast cancer: a clinical perspective. 2006 , 42, 598-607	11
1306	Mammary stem and progenitor cells: tumour precursors?. 2006 , 42, 1225-36	16
1305	What clinicians need to know about antioestrogen resistance in breast cancer therapy. 2006 , 42, 2692-705	43
1304	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. 2006 , 42, 3149-56	164
1303	WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. 2006 , 32, 153-7	68
1302	Deconstructing the molecular portrait of basal-like breast cancer. 2006 , 12, 537-44	119
1301	C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. 2006 , 37, 205-11	24
1300	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. 2006 , 37, 1217-26	259
1299	[Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. 2006 , 54, 209-14	2
1298	[DNA microarrays for gene expression profiling of breast cancer: principles and prognostic applications]. 2006 , 54, 49-54	1
1297	New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. 2006 , 1, 273-284	4
1296	Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. 2006 , 147, 4048-55	43
1295	Data Perturbation Independent Diagnosis and Validation of Breast Cancer Subtypes Using Clustering and Patterns. 2006 , 2, 117693510600200	10
1294	Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. 2006 , 28, 1327	2
1293	Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice. 2006 , 25, 194-202	35

1292	Integrative Analysis of Gene Expression Data Including an Assessment of Pathway Enrichment for Predicting Prostate Cancer. 2006 , 2, 117693510600200	1
1291	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. 2006 , 3, e47	476
1290	Predictive and Prognostic Markers in Breast Cancer Treatment âPresentations at the 28th San Antonio Breast Cancer Symposium 2005. 2006 , 1, 118-122	
1289	. 2006 ,	25
1288	Towards a Unified Approach to New Target Discovery in Breast Cancer: Combining the Power of Genomics, Proteomics and Immunology. 2006 , 167-207	
1287	Microarray-based Expression Profiling: From Technological Basics to Diagnostic Perspectives. 728-754	
1286	Carcinosarcoma of the Breast. 2006 , 218-229	1
1285	Gene Expression Profiling with DNA Microarrays. 2006 , 47-61	
1284	Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. 2006 , 107, 3189-96	77
1283	Tumor biology of breast cancer in young women. 2005 , 23, 9-15	53
1282	Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. 2006 , 4, 28-38	10
1281	Gene expression profiling of xeroderma pigmentosum. 2006 , 4, 103-10	2
1280	Personalized medicine for breast cancer: moving forward and going back. 2006 , 3, 363-370	1
1279	The role of initial trauma in the host's response to injury and hemorrhage: insights from a correlation of mathematical simulations and hepatic transcriptomic analysis. 2006 , 26, 592-600	79
1278	Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. 2006 , 9, 1-3	
1277	Gene expression pattern associated with radiotherapy sensitivity in cervical cancer. 2006 , 12, 189-93	27
1276	Molecular profiling of breast cancer. 2006 , 18, 59-63	23
1275	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. 2006 , 17, 1201-9	11

1274	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. 2006 , 30, 1097-104	206
1273	PLC- β is highly expressed in breast cancer and is associated with a poor outcome: a study on tissue microarrays. 2006 , 28, 863	1
1272	Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. 2006 , 30, 300-9	176
1271	Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes. 2006 , 208, 486-94	11
1270	Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. 2006 , 210, 420-30	61
1269	The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?. 2006 , 12, 360-2	40
1268	Gene expression patterns in advanced human cervical cancer. 2006 , 16, 562-7	24
1267	Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. 2006 , 16 Suppl 1, 152-65	41
1266	Variation within and among species in gene expression: raw material for evolution. 2006 , 15, 1197-211	259
1265	Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool. 2006 , 64, 236-42	22
1264	Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. 2006 , 49, 22-34	257
1263	Metaplastic breast carcinomas are basal-like tumours. 2006 , 49, 10-21	244
1262	Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. 2006 , 49, 248-55	15
1261	Genetic regulators of large-scale transcriptional signatures in cancer. 2006 , 38, 421-30	185
1260	Genome-wide analysis of estrogen receptor binding sites. 2006 , 38, 1289-97	1115
1259	Common markers of proliferation. 2006 , 6, 99-106	402
1258	Linking oncogenic pathways with therapeutic opportunities. 2006 , 6, 735-41	139
1257	Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. 2006 , 95, 1334-41	53

1256	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. 2006 , 19, 264-71	806
1255	Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. 2006 , 19, 307-19	75
1254	Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. 2006 , 19, 617-21	175
1253	Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. 2006 , 19, 1506-11	103
1252	Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. 2006 , 13, 706-19	14
1251	Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. 2006 , 25, 359-69	50
1250	Gene expression profiling of breast cell lines identifies potential new basal markers. 2006 , 25, 2273-84	425
1249	Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. 2006 , 25, 4429-40	84
1248	Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. 2006 , 25, 5837-45	87
1247	Basal-like breast cancer and the BRCA1 phenotype. 2006 , 25, 5846-53	368
1246	Pilot study of mucosal genetic differences in early smokers and nonsmokers. 2006 , 116, 1375-9	13
1245	Is tailored therapy feasible in oncology?. 2006 , 57, 79-101	16
1244	Stochastic dynamics of metastasis formation. 2006 , 240, 521-30	52
1243	Genetic mutations in gynaecological cancers. 2006 , 6, 115-125	3
1242	Gene expression profiling of breast cancer. 2006 , 13, 2-7	17
1241	Genetic prognostic index influences patient outcome for node-positive breast cancer. 2006 , 36, 793-801	22
1240	Timing of dietary estrogenic exposures and breast cancer risk. 2006 , 1089, 14-35	64
1239	Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. 2006 , 23, 1951-8	10

1238	BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. 2006 , 5, 135-42	114
1237	The ErbB2 signaling network as a target for breast cancer therapy. 2006 , 11, 13-25	51
1236	Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. 2006 , 95, 243-55	90
1235	cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. 2006 , 96, 17-39	49
1234	Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses. 2006 , 98, 357-64	10
1233	Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. 2006 , 99, 85-90	111
1232	Interactive Gene ClusteringâA Case Study of Breast Cancer Microarray Data. 2006 , 8, 21-27	23
1231	Predicting which children are at risk for ependymoma relapse. 2006 , 78, 41-6	28
1230	Genomic screening of head and neck cancer and its implications for therapy planning. 2006 , 263, 297-304	18
1229	Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. 2006 , 7, 67-80	270
1228	Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. 2006 , 448, 744-55	75
1227	A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles. 2006 , 132, 579-87	9
1226	Hâfoghâtâmolâculaire des cancers du sein: quelles implications pour la sâlection des patientes en vue dâune chimiothârapie adjuvante?. 2006 , 8, 235-242	
1225	Râsistances â lâhormonothârapie dans le cancer du sein. 2006 , 8, 762-766	
1224	La chimiothârapie adjuvante: quel traitement et pour qui?. 2006 , 8, 743-747	
1223	Molecular classification of tumors with special reference to EGFR mutation in lung cancer. 2006 , 58, 17-23	6
1222	[Diagnosis and immunohistochemistry of medullary breast cancer]. 2006 , 27, 358-62	4
1221	[The significance of "normal tissue" in the development of breast cancer: new concepts of early carcinogenesis]. 2006 , 27, 319-25	0

1220	Gene expression in breast cancer. 2006 , 7, 123-8	19
1219	X chromosomal abnormalities in basal-like human breast cancer. 2006 , 9, 121-32	649
1218	The challenges of gene expression microarrays for the study of human cancer. 2006 , 9, 333-9	80
1217	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. 2006 , 10, 515-27	2386
1216	Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. 2006 , 10, 529-41	998
1215	Integrated breast cancer genomics. 2006 , 10, 453-4	3
1214	DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design. 2006 , 1766, 197-204	12
1213	SAGE and related approaches for cancer target identification. 2006 , 11, 110-8	27
1212	Neoadjuvant endocrine therapy for locally advanced breast cancer. 2006 , 33, 650-6	18
1211	Clinicians' guide to microarrays. 2006 , 15, 205-10	4
1210	Gene expression patterns associated with p53 status in breast cancer. 2006 , 6, 276	107
1209	Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. 2006 , 4, 16	40
1208	Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. 2006 , 7, 141-5	12
1207	Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. 2006 , 7, 197	201
1206	Profiling alternatively spliced mRNA isoforms for prostate cancer classification. 2006 , 7, 202	78
1205	WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. 2006 , 7, 30	177
1204	Improving missing value imputation of microarray data by using spot quality weights. 2006 , 7, 306	20
1203	Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. 2006 , 7, 127	262

1202	Discovery and validation of breast cancer subtypes. 2006 , 7, 231	87
1201	Converting a breast cancer microarray signature into a high-throughput diagnostic test. 2006 , 7, 278	366
1200	The molecular portraits of breast tumors are conserved across microarray platforms. 2006 , 7, 96	1016
1199	Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. 2006 , 209, 645-52	106
1198	From differential display to DNA microarrays--a personal account. 2006 , 209, 653-8	7
1197	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. 2006 , 45, 1033-40	410
1196	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. 2006 , 106, 693-702	24
1195	ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. 2006 , 118, 1241-7	66
1194	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. 2006 , 118, 1699-712	120
1193	Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. 2006 , 119, 2974-9	37
1192	Co-regulation of B-Myb expression by E2F1 and EGF receptor. 2006 , 45, 10-7	135
1191	From description to causality: mechanisms of gene expression signatures in cancer. 2006 , 5, 1148-51	19
1190	The basal phenotype of BRCA1-related breast cancer: past, present and future. 2006 , 5, 963-7	43
1189	Classification of breast cancer using genetic algorithms and tissue microarrays. 2006 , 12, 6459-68	88
1188	A step in the right direction. 2006 , 24, 3717-8	13
1187	Association of prolactin and its receptor gene regions with familial breast cancer. 2006 , 91, 1513-9	43
1186	TOM: a web-based integrated approach for identification of candidate disease genes. 2006 , 34, W285-92	50
1185	Breast cancer expression profiling: the impact of microarray testing on clinical decision making. 2006 , 7, 2069-78	7

1184	Functional interrogation of breast cancer: from models to drugs. 2006 , 1, 569-84	3
1183	Use of gene expression microarrays for the study of acute leukemia. 2006 , 6, 733-47	1
1182	Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophosphamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. 2006 , 128, 76-81	19
1181	Proliferation: the most prominent predictor of clinical outcome in breast cancer. 2006 , 5, 2198-202	67
1180	Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. 2006 , 147, 700-13	42
1179	Clustering microarray data. 2006 , 411, 194-213	31
1178	A review of the ethnic differences in breast cancer. 2006 , 7, 935-42	39
1177	Characterization of RERG: an estrogen-regulated tumor suppressor gene. 2006 , 407, 513-27	15
1176	Novel patterns of genome rearrangement and their association with survival in breast cancer. 2006 , 16, 1465-79	256
1175	Translating genomic biomarkers into clinically useful diagnostics. 2006 , 6, 179-91	46
1174	The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. 2006 , 12, 6000-4	11
1173	CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. 2006 , 12, 6421-31	111
1172	Gene Expression Profiling of Epithelial Ovarian Cancer. 2006 , 7, 115-135	3
1171	Genome-scale identification of membrane-associated human mRNAs. 2006 , 2, e11	76
1170	Basal-like breast carcinomas: clinical outcome and response to chemotherapy. 2006 , 59, 729-35	213
1169	The impact of expression profiling on prognostic and predictive testing in breast cancer. 2006 , 59, 225-31	93
1168	Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. 2006 , 17, 588-96	62
1167	A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. 2006 , 3, e467	243

1166	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. 2006 , 98, 1183-92	976
1165	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. 2006 , 5, 2572-9	67
1164	Molecular forecasting of breast cancer: time to move forward with clinical testing. 2006 , 24, 721-2; author reply 722-3	16
1163	Steroid hormone receptor status of mouse mammary stem cells. 2006 , 98, 1011-4	244
1162	Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. 2006 , 12, 3184-92	119
1161	ATF3 regulates the stability of p53: a link to cancer. 2006 , 5, 926-9	58
1160	Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. 2006 , 12, 1693-700	31
1159	Evaluation of Her-2/neu Status in Carcinomas With Amplified Chromosome 17 Centromere Locus. 2006 , 126, 709-716	52
1158	A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. 2006 , 12, 3288-96	37
1157	Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. 2006 , 5, 2914-8	103
1156	Molecular Diagnosis of Breast Cancer. 2006 , 201-233	
1155	Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. 2006 , 66, 10292-301	531
1154	Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. 2006 , 5, 565-71	11
1153	The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms. 2006 , 43, 424-9	38
1152	Biphasic metaplastic sarcomatoid carcinoma of the breast. 2006 , 17, 605-13	138
1151	Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. 2006 , 12, 1168-74	223
1150	Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. 2006 , 66, 11279-86	70
1149	The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. 2006 , 24, 4611-9	208

1148	Drugs Affecting Growth of Tumours. 2006 ,	1
1147	Bioinformatics for cancer management in the post-genome era. 2006 , 5, 169-75	41
1146	Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. 2006 , 24, 2113-22	90
1145	Chips to bedside: incorporation of microarray data into clinical practice. 2006 , 12, 7209-14	24
1144	Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. 2006 , 12, 2468-75	163
1143	Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. 2006 , 66, 4872-9	129
1142	Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. 2006 , 12, 4185-91	88
1141	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 2006 , 295, 2492-502	2683
1140	Gene expression profiling in breast cancer. 2006 , 17 Suppl 10, x259-62	24
1139	Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. 2006 , 3, 138-51	46
1138	A survey of methods for classification of gene expression data using evolutionary algorithms. 2006 , 6, 101-10	13
1137	Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. 2006 , 24, 1839-45	129
1136	Demystifying basal-like breast carcinomas. 2007 , 60, 1328-32	41
1135	Underexpression of transcriptional regulators is common in metastatic breast cancer cells overexpressing Bcl-xL. 2006 , 27, 1169-79	8
1134	Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. 2006 , 24, 3039-47	150
1133	Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. 2006 , 66, 11399-408	53
1132	A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. 2006 , 12, 2080-7	136
1131	Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. 2006 , 12, 5047-54	69

1130	Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. 2006 , 12, 5705-12	51
1129	Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. 2006 , 5, 43-52	17
1128	Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. 2006 , 24, 1656-64	275
1127	Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. 2006 , 6, 455-89	28
1126	Survival analysis of longitudinal microarrays. 2006 , 22, 2643-9	7
1125	Protein Microarrays. 2006 ,	
1124	Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database. 2006 , 7, 1025-44	100
1123	Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. 2006 , 66, 2361-6	73
1122	Analysis of SNP-expression association matrices. 2006 , 4, 259-74	3
1121	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. 2006 , 12, 1157-67	414
1120	Genetic variation in putative regulatory loci controlling gene expression in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 7735-40	11.5 26
1119	Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5923-8	11.5 528
1118	Molecular classification of breast cancer: limitations and potential. 2006 , 11, 868-77	150
1117	Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. 2006 , 12, 781-90	36
1116	Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. 2006 , 24, 1332-41	187
1115	Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. 2006 , 12, 3896-901	32
1114	Gene expression profile exploration of a large dataset on chronic fatigue syndrome. 2006 , 7, 429-40	48
1113	Tissue detection of biomolecular predictors in breast cancer. 2006 , 6, 1225-32	4

1112	Profiling activities of transcription factors in breast cancer cell lines. 2006 , 4, 293-305		13
1111	Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. 2007 , 8, 32-44		452
1110	A positive role for PEA3 in HER2-mediated breast tumour progression. 2006 , 95, 1404-9		24
1109	Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. 2006 , 95, 616-26		106
1108	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. 2006 , 3, 621-32		100
1107	Gene expression profiles of head and neck carcinomas from Sudanese and Norwegian patients reveal common biological pathways regardless of race and lifestyle. 2006 , 12, 1109-20		17
1106	Breast cancer in African-American women: differences in tumor biology from European-American women. 2006 , 66, 8327-30		142
1105	Vascular Endothelial Growth Factor Expression in the Basal Subtype of Breast Carcinoma. 2006 , 125, 512-518		35
1104	Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. 2006 , 12, 3950-60		124
1103	Identification of alterations in DNA copy number in host stromal cells during tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 19848-53	11.5	45
1102	Heterogeneous nuclear ribonucleoprotein-A2/B1 modulate collagen prolyl 4-hydroxylase, alpha (I) mRNA stability. 2006 , 281, 9279-86		37
1101	Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 10069-74	11.5	446
1100	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. 2007 , 67, 2226-38		272
1099	Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. 2007 , 67, 2990-3001		29
1098	Framework for Identifying Common Aberrations in DNA Copy Number Data. 2007 , 122-136		6
1097	Reconstructing tumor phylogenies from heterogeneous single-cell data. 2007 , 5, 407-27		32
1096	The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. 2007 , 67, 10230-40		68
1095	Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. 2007 , 67, 75-84		140

1094	Clinical and therapeutic perspectives of gene expression profiling for breast cancer. 2007 , 18 Suppl 6, vi58-62	3
1093	The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. 2007 , 72, 641-52	30
1092	Disease-specific genomic analysis: identifying the signature of pathologic biology. 2007 , 23, 957-65	42
1091	Population-based molecular prognosis of breast cancer by transcriptional profiling. 2007 , 13, 2014-22	25
1090	The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 7570-5	11.5 112
1089	<i>Saccharomyces cerevisiae</i> signature genes for predicting nitrogen deficiency during alcoholic fermentation. 2007 , 73, 5363-9	20
1088	Are clusters found in one dataset present in another dataset?. 2007 , 8, 9-31	113
1087	PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. 2007 , 97, 809-17	39
1086	Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. 2007 , 7, 1243-53	7
1085	Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. 2007 , 67, 10608-17	46
1084	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. 2007 , 103-120	
1083	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. 2008 , 61, 327-32	87
1082	Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. 2007 , 147-158	
1081	Breast cancer prognostication and prediction: are we making progress?. 2007 , 18 Suppl 8, viii3-7	42
1080	Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. 2007 , 67, 9169-79	66
1079	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. 2007 , 18, 1477-83	66
1078	Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. 2007 , 46, 1178-83	32
1077	Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. 2007 , 67, 8643-52	78

1076	Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. 2007 , 4, e90	132
1075	Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. 2007 , 46, 153-64	43
1074	Gene expression programs of human smooth muscle cells: tissue-specific differentiation and prognostic significance in breast cancers. 2007 , 3, 1770-84	48
1073	Breast cancer prognostication and prediction in the postgenomic era. 2007 , 18, 1293-306	46
1072	Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. 2007 , 18, 1021-9	120
1071	Nutritional modulation of terminal end buds: its relevance to breast cancer prevention. 2007 , 7, 465-74	66
1070	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. 2007 , 25, 1239-46	650
1069	p63, cell adhesion and survival. 2007 , 6, 255-61	38
1068	Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. 2007 , 6, 643-6	17
1067	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. 2007 , 11, 1287-98	23
1066	Conventional and new emerging prognostic factors in breast cancer: an update. 2007 , 1, 525-40	3
1065	Application of Genomics in Clinical Oncology. 2007 , 26, 79-93	1
1064	Gene-expression analysis and the basal-like breast cancer subtype. 2007 , 3, 55-63	29
1063	Adjuvante Therapie des Mammarkarzinoms - Bericht über die 10. Internationale Expertenkonsensuskonferenz St. Gallen 2007: "Care Despite Controversies" 2007 , 67, 460-467	0
1062	Breast tumor heterogeneity: cancer stem cells or clonal evolution?. 2007 , 6, 2332-8	313
1061	Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. 2007 , 67, 6477-83	274
1060	Self-self hybridization as an alternative experiment design to dye swap for two-color microarrays. 2007 , 11, 14-24	8
1059	Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. 2007 , 3, 805-17	42

1058	FOX M1, a typical proliferation-associated transcription factor. 2007 , 388, 1257-74	215
1057	Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. 2007 , 18, 1904-6	30
1056	Data Mining and Clinical Decision Support Systems. 2007 , 44-63	22
1055	Women's interest in gene expression analysis for breast cancer recurrence risk. 2007 , 25, 4628-34	38
1054	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. 2007 , 13, 4415-21	187
1053	Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. 2007 , 6, 1973-82	71
1052	Osteoactivin promotes breast cancer metastasis to bone. 2007 , 5, 1001-14	130
1051	A supervised approach for identifying discriminating genotype patterns and its application to breast cancer data. 2007 , 23, e91-8	15
1050	Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. 2007 , 13, 1198-207	202
1049	What can breast cancer molecular sub-classification add to conventional diagnostic tools?. 2007 , 18 Suppl 9, ix33-6	4
1048	Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. 2007 , 67, 11147-57	69
1047	BRCA1, a potential predictive biomarker in the treatment of breast cancer. 2007 , 12, 142-50	125
1046	Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. 2007 , 25, 5194-202	208
1045	BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. 2007 , 67, 6725-36	72
1044	Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. 2007 , 6, 1997-2011	164
1043	Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. 2007 , 13, 488-97	59
1042	Challenges in projecting clustering results across gene expression-profiling datasets. 2007 , 99, 1715-23	73
1041	Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status. 2007 , 16, 2269-75	15

1040	Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. 2007 , 13, 1115-22	59
1039	Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. 2007 , 5, 881-90	88
1038	Adaptation of energy metabolism in breast cancer brain metastases. 2007 , 67, 1472-86	249
1037	Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. 2007 , 13, 5314-21	101
1036	Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?. 2007 , 13, 1071-3	
1035	Notch, Myc and breast cancer. 2007 , 6, 418-29	61
1034	Breast Cancer. 2007 ,	
1033	Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. 2007 , 18, 1133-44	695
1032	Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. 2007 , 13, 7029-36	94
1031	Prognostic and Predictive Value of TP53 Mutations in Human Cancer. 2007 , 321-338	8
1030	Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 10888-93	11.5 46
1029	Experimental Design for Gene Expression Analysis. 2007 , 29-44	2
1028	Integrated profiling of basal and luminal breast cancers. 2007 , 67, 11565-75	232
1027	Potential chemotherapy options in the triple negative subtype of breast cancer. 2007 , 25, 1294-5; author reply 1295-6	11
1026	In Reply. 2007 , 25, 1295-1296	6
1025	In Reply. 2007 , 25, 1294-1294	6
1024	Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. 2007 , 67, 501-10	101
1023	Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. 2007 , 67, 1680-8	50

1022	Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. 2007 , 67, 6825-43	38
1021	Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. 2007 , 67, 8065-80	90
1020	The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. 2007 , 13, 6327-34	59
1019	Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. 2007 , 282, 14413-20	65
1018	Molecular restoration of archived transcriptional profiles by complementary-template reverse-transcription (CT-RT). 2007 , 35, e94	25
1017	DNA Microarray Technology and Applications – An Overview. 899-928	
1016	Gene expression signatures to predict the development of metastasis in breast cancer. 2006 , 26, 149-56	15
1015	Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers. 2007 , 5, 119-43	
1014	Breast. 2007 ,	
1013	The phenotypic spectrum of basal-like breast cancers: a critical appraisal. 2007 , 14, 358-73	64
1012	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. 2007 , 110, 3015-27	96
1011	St. Gallen 2007: Breast Cancer Treatment Consensus Report. 2007 , 2, 130-134	25
1010	Hypoxia and metastasis in breast cancer. 2006 , 26, 55-64	44
1009	Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling. 2007 , 28, 39-51	12
1008	DNA Microarray and Breast Cancer-A Review. 2007 , 7, 49-56	3
1007	Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. 2007 , 18, 499-523	16
1006	Understanding systemic sclerosis through gene expression profiling. 2007 , 19, 561-7	4
1005	Gene expression profiling in breast cancer. 2007 , 19, 547-51	40

1004	Use of immunohistochemistry in diagnosis of breast epithelial lesions. 2007 , 14, 93-107	36
1003	Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. 2007 , 14, 419-30	97
1002	Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. 2007 , 31, 501-8	53
1001	Immunohistochemical staining of papillary breast lesions. 2007 , 15, 145-53	12
1000	Basal-Like Breast Cancers. 2007 , 12, 143-153	7
999	Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. 2007 , 31, 247-54	5
998	Gene expression profile as a prognostic factor in high-grade gliomas. 2007 ,	
997	Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray. 2007 , 25, 120-7	3
996	[DNA microarrays: technology and new insights in oncology]. 2007 , 28, 662-6	
995	Targeting integrin beta4 for cancer and anti-angiogenic therapy. 2007 , 28, 506-11	105
994	The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. 2007 , 67, 6574-81	115
993	Anti-apoptotic, Tumorigenic and Metastatic Potential of Hsp27 (HspB1) and B-crystallin (HspB5): Emerging Targets for the Development of New Anti-Cancer Therapeutic Strategies. 2007 , 73-92	5
992	Selective discussion and transparency in microarray research findings for cancer outcomes. 2007 , 43, 1999-2010	14
991	Molecular profiling techniques and bioinformatics in cancer research. 2007 , 33, 255-65	15
990	Prognostic factors in invasive breast carcinoma: Do new molecular techniques/profiling add significantly to traditional histological factors?. 2007 , 13, 116-125	
989	Arylamine N-acetyltransferase I. 2007 , 39, 1999-2005	59
988	Integrin signaling in epithelial cells. 2007 , 247, 1-25	148
987	Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. 2007 , 143, 109-18	113

986	Distinct mechanisms of tumor invasion and metastasis. 2007 , 13, 535-41	175
985	Identification of a basal-like subtype of breast ductal carcinoma in situ. 2007 , 38, 197-204	166
984	PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. 2007 , 38, 1425-31	24
983	Progress and new standards of care in the management of HER-2 positive breast cancer. 2007 , 43, 497-509	52
982	Current immunotherapeutic strategies in pancreatic cancer. 2007 , 16, 919-43, xi	7
981	A perspective on DNA microarrays in pathology research and practice. 2007 , 171, 375-85	42
980	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. 2007 , 13, 2329-34	1534
979	Primary systemic chemotherapy of invasive lobular carcinoma of the breast. 2007 , 8, 55-62	77
978	Triple-negative breast cancer: therapeutic options. 2007 , 8, 235-44	664
977	Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics. 2007 , 46, 222-9	11
976	Classification moléculaire des cancers du sein: vers une classification prédictive. 2007 , 297-305	
975	Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression. 2007 , 121, 474-85	15
974	CYCLONET--an integrated database on cell cycle regulation and carcinogenesis. 2007 , 35, D550-6	13
973	Developments in the systemic therapy of early-stage breast cancer. 2007 , 5, 3-10	2
972	To bury TNM classification in breast cancer or to praise it?. 2007 , 5, 23-29	
971	Biomarkers for therapeutic efficacy. 2007 , 5, 129-142	4
970	Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. 2007 , 9, 327-36	34
969	Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. 2007 , 9, 113	35

968	International Web-based consultation on priorities for translational breast cancer research. 2007 , 9, R81	76
967	Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. 2007 , 9, 110	17
966	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. 2007 , 9, R59	53
965	Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. 2007 , 9, R61	112
964	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. 2007 , 9, R65	454
963	Amping up estrogen receptors in breast cancer. 2007 , 9, 305	16
962	Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation. 2007 , 9, R36	21
961	Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. 2007 , 9, R34	70
960	Molecular response to aromatase inhibitor treatment in primary breast cancer. 2007 , 9, R37	97
959	TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. 2007 , 9, R30	208
958	Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. 2007 , 9, R33	52
957	Adjuvant treatment: the contribution of expression microarrays. 2007 , 9,	1
956	Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. 2007 , 9, 206	33
955	Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. 2007 , 9, R21	18
954	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. 2007 , 9, R24	130
953	The continuing search for cancer-causing somatic mutations. 2007 , 9, 101	2
952	Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. 2007 , 9, R5	23
951	Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. 2007 , 9, R16	101

950	Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. 2007 , 9, R4	230
949	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. 2007 , 8, R215	230
948	MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. 2007 , 8, R214	742
947	Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. 2007 , 8, R191	65
946	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. 2007 , 8, R76	880
945	FOXA1 as a therapeutic target for breast cancer. 2007 , 11, 507-14	52
944	Novel agents in ovarian cancer. 2007 , 16, 1227-39	9
943	Molecular Pathology in Clinical Practice. 2007 ,	3
942	Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. 2007 , 67, 8504-10	221
941	RNA and protein clean-up from the same specimen. Comparison between the Qiagen and Ambion protocols. 2007 , 67, 885-91	
940	Transcriptomic signatures in breast cancer. 2007 , 3, 466-72	9
939	Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management. 2007 , 7, 269-80	11
938	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. 2007 , 25, 5287-312	1760
937	High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. 2007 , 67, 10669-76	167
936	The prognostic role of a gene signature from tumorigenic breast-cancer cells. 2007 , 356, 217-26	826
935	Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. 2007 , 53, 1273-9	57
934	Triple-negative breast cancer: clinical features and patterns of recurrence. 2007 , 13, 4429-34	2961
933	Classification pronostique du cancer du sein et transcriptome. 2007 , 27, 48-50	

932	Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. 2007 , 9, 788-96	21
931	Breast Conservation Therapy and the Role of the Surgical Pathologist. 2007 , 10, 166-168	1
930	Locoregional Resection in Stage IV breast cancer: tumor biology, molecular and clinical perspectives. 2007 , 87, 527-38, xi-xii	8
929	Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer. 2007 , 4, 677-87	35
928	Anatomy Versus Biology: To What Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy?. 2007 , 18, 232-234	
927	Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. 2007 , 1, 97-119	29
926	Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. 2007 , 1, 160-71	121
925	Identifying estrogen receptor target genes. 2007 , 1, 138-43	54
924	Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. 2007 , 1, 321-49	23
923	The MINDACT trial: the first prospective clinical validation of a genomic tool. 2007 , 1, 246-51	97
922	Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. 2007 , 6, 2	52
921	Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized. 2007 , 6, 7	42
920	Origins of breast cancer subtypes and therapeutic implications. 2007 , 4, 516-25	126
919	Expression technology - A review of the performance and interpretation of expression microarrays. 2007 , 24, 18-26	4
918	Proteomic expression profiling of breast cancer. 2007 , 176, 89-120	5
917	Predicting risk of breast cancer recurrence using gene-expression profiling. 2007 , 8, 101-11	10
916	Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. 2007 , 11, 355-60	18
915	Characterization of breast cancer by array comparative genomic hybridization. 2007 , 85, 497-508	33

914	Etiology of specific molecular alterations in human malignancies. 2007 , 118, 277-83	5
913	Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. 2007 , 8, 1359-68	3
912	Partners in research: benefits of a summer research program. 2006 , 21, 243-7	7
911	Genomic signatures of breast cancer metastasis. 2007 , 118, 116-29	7
910	[Mammary stem and progenitor cells: critical role of the transcription factor Gata-3]. 2007 , 23, 1077-80	5
909	Gene expression patterns in pancreatic tumors, cells and tissues. 2007 , 2, e323	74
908	Module-based outcome prediction using breast cancer compendia. 2007 , 2, e1047	23
907	Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. 2007 , 23, 189-96	18
906	Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. 2007 , 43, 41-2, 44, 46 passim	25
905	Breast cancer: origins and evolution. 2007 , 117, 3155-63	369
904	Public Databases and Software for the Pathway Analysis of Cancer Genomes. 2007 , 3, 117693510700300	9
903	[Exquisite sensitivity of TP53 mutant breast cancers to dose-dense chemotherapy]. 2007 , 23, 1021-3	2
902	[Gene expression profiles for therapeutic decisions in breast cancer]. 2007 , 135, 257-63	
901	. 2007 ,	5
900	Supervised classification of combined copy number and gene expression data. 2007 , 4, 168-185	5
899	Censored Data Regression in High-Dimensional and Low-Sample-Size Settings for Genomic Applications. 385-403	1
898	Elucidation of a protein signature discriminating six common types of adenocarcinoma. 2007 , 120, 769-75	30
897	Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. 2007 , 121, 683-8	26

896	A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. 2007 , 121, 1036-46	23
895	Moesin expression is a marker of basal breast carcinomas. 2007 , 121, 1779-85	63
894	Gene expression abnormalities in histologically normal breast epithelium of breast cancer patients. 2008 , 122, 1557-66	90
893	Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches. 2007 , 101, 1074-86	9
892	Gene expression in 16q is associated with survival and differs between Sflie breast cancer subtypes. 2007 , 46, 87-97	15
891	Prognostic markers in triple-negative breast cancer. 2007 , 109, 25-32	963
890	Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. 2007 , 109, 496-501	37
889	Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 2007 , 109, 1011-8	154
888	Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. 2007 , 109, 1721-8	1505
887	Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. 2007 , 110, 1130-8	224
886	Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. 2007 , 110, 1687-96	73
885	Racial disparities in breast cancer outcome: insights into host-tumor interactions. 2007 , 110, 1880-8	41
884	The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. 2007 , 61, 187-94	37
883	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?. 2007 , 62, 1-8	2
882	Genetic susceptibility for breast cancer: how many more genes to be found?. 2007 , 63, 125-49	86
881	Optimization of oligonucleotide microarray fabricated by spotting 65-mer. 2007 , 368, 61-9	8
880	Puces ^ADN. 2007 , 28, 210-215	5
879	RNA quality in frozen breast cancer samples and the influence on gene expression analysis--a comparison of three evaluation methods using microcapillary electrophoresis traces. 2007 , 8, 38	83

878	Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines after acid or bile salt exposure. 2007 , 7, 24	16
877	A mouse model of basal-like breast carcinoma with metaplastic elements. 2007 , 211, 389-98	118
876	Morphological features of TMPRSS2-ERG gene fusion prostate cancer. 2007 , 212, 91-101	96
875	Predictive medicine: incipient reality or fata morgana?. 2007 , 212, 353-5	5
874	NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. 2007 , 26, 711-24	477
873	Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. 2007 , 26, 1959-70	88
872	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. 2007 , 26, 2157-65	646
871	Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. 2007 , 26, 6269-79	32
870	An update on apocrine lesions of the breast. 2008 , 52, 3-10	64
869	Triple negative tumours: a critical review. 2008 , 52, 108-18	640
868	Expression profiling technology: its contribution to our understanding of breast cancer. 2008 , 52, 67-81	34
867	Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. 2007 , 9, 201-9	618
866	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. 2007 , 7, 937-48	339
865	Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. 2007 , 7, 545-53	382
864	Modelling breast cancer: one size does not fit all. 2007 , 7, 659-72	481
863	Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. 2007 , 7, 713-22	167
862	Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. 2007 , 7, 791-9	365
861	Genetic determinants of cancer metastasis. 2007 , 8, 341-52	624

860	RNA expression analysis of formalin-fixed paraffin-embedded tumors. 2007 , 87, 383-91	136
859	Quantitative analysis of estrogen receptor heterogeneity in breast cancer. 2007 , 87, 662-9	97
858	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. 2007 , 20, 474-81	179
857	High-level JAG1 mRNA and protein predict poor outcome in breast cancer. 2007 , 20, 685-93	168
856	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). 2007 , 20, 1200-7	64
855	Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. 2007 , 20, 1298-306	44
854	Vitamin D regulates the phenotype of human breast cancer cells. 2007 , 75, 193-207	101
853	TACE: a new target in epidermal growth factor receptor dependent tumors. 2007 , 75, 800-8	55
852	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. 2007 , 50, 434-8	132
851	Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. 2007 , 51, 354-61	34
850	Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA. 2007 , 51, 829-36	14
849	Increased phosphorylation of Akt in triple-negative breast cancers. 2007 , 98, 1889-92	53
848	The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. 2007 , 13, 130-9	33
847	Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. 2007 , 13, 172-9	59
846	Frequency of the basal-like phenotype in African breast cancer. 2007 , 115, 1391-9	33
845	Epidermal growth factor receptor mutations in lung cancers. 2007 , 57, 233-44	60
844	Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 2007 , 7, 841-9	12
843	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. 2007 , 7, 134	284

842	An integrated analysis of genes and pathways exhibiting metabolic differences between estrogen receptor positive breast cancer cells. 2007 , 7, 181	10
841	Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. 2007 , 7, 182	94
840	Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. 2007 , 7, 203	111
839	A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. 2007 , 7, 39	14
838	Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. 2007 , 7, 55	287
837	Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. 2007 , 7, 59	153
836	Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. 2007 , 7, 61	29
835	Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. 2007 , 7, 63	55
834	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. 2007 , 7, 73	102
833	Re-sampling strategy to improve the estimation of number of null hypotheses in FDR control under strong correlation structures. 2007 , 8, 157	17
832	SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets. 2007 , 8, 422	9
831	Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. 2007 , 8, 148	38
830	A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. 2007 , 8, 199	10
829	EGFR associated expression profiles vary with breast tumor subtype. 2007 , 8, 258	208
828	Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. 2007 , 8, 279	38
827	Integrated analysis of independent gene expression microarray datasets improves the predictability of breast cancer outcome. 2007 , 8, 331	19
826	Expression and genomic profiling of colorectal cancer. 2007 , 1775, 103-37	65
825	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. 2007 , 16, 73-80	14

824	Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. 2007 , 16, 86-93	62
823	The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. 2007 , 16, 104-7	111
822	The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. 2007 , 16, 235-40	53
821	Using clinical trial data to tailor adjuvant treatments for individual patients. 2007 , 16 Suppl 2, S98-104	4
820	Using specific cytotoxics with a targeted mind. 2007 , 16 Suppl 2, S120-6	31
819	The evolution of treatment strategies: aiming at the target. 2007 , 16 Suppl 2, S10-6	25
818	Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast. 2007 , 178, 94-103	14
817	Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. 2007 , 12, 160-70	255
816	Shaping genetic alterations in human cancer: the p53 mutation paradigm. 2007 , 12, 303-12	288
815	ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. 2007 , 12, 542-58	115
814	Biological basis of breast cancer: an introduction. 2007 , 34, S1-3	
813	Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. 2007 , 14, 156-62	18
812	cDNA Labeling Strategies for Microarrays Using Fluorescent Dyes. 2007 , 7, 26-34	7
811	Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. 2007 , 14, 2994-3003	36
810	Molekulares Staging und Vorhersage von Therapieansprechen beim Mammakarzinom. 2007 , 40, 424-430	
809	Molecular basis of invasion in breast cancer. 2007 , 64, 3201-18	70
808	Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. 2007 , 64, 3219-32	20
807	Hypoxia and breast cancer: prognostic and therapeutic implications. 2007 , 64, 3233-47	91

806	Mammary stem cells and breast cancer. 2007 , 64, 3248-60	45
805	Molecular profiling in breast cancer. 2007 , 8, 185-98	34
804	Modeling metastatic breast cancer in mice. 2007 , 12, 191-203	53
803	Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. 2007 , 102, 31-41	51
802	Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. 2007 , 103, 197-208	65
801	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. 2007 , 105, 319-26	34 ²
800	Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. 2007 , 106, 181-9	94
799	Femara and the future: tailoring treatment and combination therapies with Femara. 2007 , 105 Suppl 1, 105-15	12
798	Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. 2007 , 24, 317-27	22
797	Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. 2007 , 24, 411-22	24
796	Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. 2007 , 24, 575-85	23
795	Prädiktive Biomarker. 2007 , 13, 56-66	0
794	An introduction to biomarkers: applications to chronic kidney disease. 2007 , 22, 1849-59	16
793	P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. 2007 , 450, 73-80	62
792	Comparison of RNA amplification techniques meeting the demands for the expression profiling of clinical cancer samples. 2007 , 451, 1019-29	9
791	HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy. 2007 , 133, 423-9	18
790	Studies of differentially-expressed genes in human endometrial cancer of various differentiated grades. 2007 , 4, 77-82	2
789	The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective. 2007 , 9, 752-9	5

788	Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome. 2008 , 107, 225-34	51
787	Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. 2008 , 107, 405-14	24
786	Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. 2008 , 108, 251-8	20
785	Predicting features of breast cancer with gene expression patterns. 2008 , 108, 191-201	180
784	Epidemiology of basal-like breast cancer. 2008 , 109, 123-39	651
783	The role of cyclooxygenase-2 in breast cancer: review. 2008 , 109, 189-98	91
782	HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. 2008 , 109, 351-7	29
781	Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. 2008 , 109, 491-501	33
780	Immunohistochemical and molecular subtypes of breast cancer in Nigeria. 2008 , 110, 183-8	84
779	Consensus genes of the literature to predict breast cancer recurrence. 2008 , 110, 235-44	23
778	Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. 2008 , 110, 245-56	57
777	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. 2008 , 111, 27-44	257
776	alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. 2008 , 111, 411-7	57
775	JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. 2008 , 111, 439-48	123
774	Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. 2008 , 111, 405-10	112
773	Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia. 2008 , 112, 237-41	7
772	New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. 2008 , 112, 453-9	29
771	Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. 2008 , 112, 489-501	28

770	Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. 2008 , 27, 75-83	67
769	Multiple biomarker tissue microarrays: bioinformatics and practical approaches. 2008 , 27, 481-94	23
768	The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. 2008 , 27, 575-87	17
767	The relevance of mouse models to understanding the development and progression of human breast cancer. 2008 , 13, 279-88	30
766	Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. 2008 , 13, 485-98	120
765	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. 2008 , 61, 965-71	18
764	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. 2008 , 62, 667-72	74
763	[Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?]. 2008 , 29 Suppl 2, 363-9	
762	[Aquaporin 1 expression in invasive breast carcinomas]. 2008 , 29 Suppl 2, 357-62	11
761	Festschrift for Professor Niall O'Higgins. January 26, 2007. Dublin, Ireland. 2008 , 177 Suppl 4, 109-63	
760	Scleroderma gene expression and pathway signatures. 2008 , 10, 205-11	13
759	Personalized systemic treatment for breast cancer patients: is it a reality?. 2008 , 15, 141-4	1
758	Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. 2008 , 15, 117-20	15
757	Individualization of breast cancer based on histopathological features and molecular alterations. 2008 , 15, 121-32	17
756	Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. 2008 , 15, 153-8	29
755	Is triple negative a prognostic factor in breast cancer?. 2008 , 15, 303-8	80
754	Validation and quality control of protein microarray-based analytical methods. 2008 , 38, 19-31	32
753	The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. 2008 , 10, 78-84	26

752	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. 2008 , 10, 552-9	1
751	Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. 2008 , 10, 646-53	45
750	"New" molecular taxonomy in breast cancer. 2008 , 10, 777-85	13
749	Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. 2008 , 41, 117-20	13
748	The human keratins: biology and pathology. 2008 , 129, 705-33	909
747	RNA expression analysis from formalin fixed paraffin embedded tissues. 2008 , 130, 435-45	151
746	Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. 2008 , 453, 123-32	111
745	Early indicators of exposure to biological threat agents using host gene profiles in peripheral blood mononuclear cells. 2008 , 8, 104	7
744	Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. 2008 , 1, 11	58
743	Pathway analysis reveals functional convergence of gene expression profiles in breast cancer. 2008 , 1, 28	29
742	Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. 2008 , 1, 39	22
741	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. 2008 , 1, 42	95
740	Expression profiling with RNA from formalin-fixed, paraffin-embedded material. 2008 , 1, 9	48
739	Reasons for breast cancer heterogeneity. 2008 , 7, 6	57
738	The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. 2008 , 214, 25-37	138
737	Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. 2008 , 214, 357-67	264
736	Small is beautiful: microRNAs and breast cancer-where are we now?. 2008 , 215, 214-21	59
735	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. 2008 , 215, 398-410	116

734	Refinement of breast cancer classification by molecular characterization of histological special types. 2008 , 216, 141-50	404
733	Breast cancer special types: why bother?. 2008 , 216, 394-8	57
732	The genomic profile of HER2-amplified breast cancers: the influence of ER status. 2008 , 216, 399-407	69
731	Gene expression profiling as a tool for basic analysis and clinical application of human cancer. 2008 , 47, 573-9	16
730	Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. 2008 , 97, 30-4	36
729	Current NCI-sponsored Cooperative Group trials of endocrine therapies in breast cancer. 2008 , 112, 723-729	5
728	Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. 2008 , 112, 731-6	50
727	Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful	190
726	The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. 2008 , 112, 737-47	112
725	Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. 2008 , 112, 1575-84	55
724	The molecular journey from ductal carcinoma in situ to invasive breast cancer. 2008 , 112, 2130-42	99
723	High prevalence of triple-negative tumors in an urban cancer center. 2008 , 113, 608-15	65
722	Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. 2008 , 113, 1521-6	102
721	Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. 2008 , 113, 1511-20	90
720	Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. 2008 , 113, 2638-45	438
719	High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. 2008 , 29, 757-64	41
718	A stromal gene signature associated with inflammatory breast cancer. 2008 , 122, 1324-32	134
717	How basal are triple-negative breast cancers?. 2008 , 123, 236-40	336

716	Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. 2008 , 123, 1433-8	63
715	Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. 2008 , 123, 1327-38	68
714	Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. 2008 , 123, 1807-15	38
713	Tissue culture-based breast cancer biomarker discovery platform. 2008 , 123, 2007-12	60
712	Evolving strategies for global gene expression analysis of cancer. 2008 , 217, 590-7	9
711	DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. 2008 , 47, 490-9	79
710	Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. 2008 , 47, 680-96	73
709	Molecular Basis of Breast Cancer. 2022 , 3-15	
708	SOX10 is a highly specific biomarker of basal-like breast cancer. 2021 ,	1
707	Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database. 2020 , 21, 3587-3593	5
706	Time-to-Event Analysis for Recovery from Coronavirus Disease (COVID-19): A Case Study on Wuhan and Elsewhere in China from Jan 1 to Feb 11, 2020. 2020 , 5, 1609-1617	
705	The nature of triple-negative breast cancer classification and antitumoral strategies. 2020 , 18, e35	
704	A Mechanistic Investigation on the Anticancer Properties of SYA013, a Homopiperazine Analogue of Haloperidol with Activity against Triple Negative Breast Cancer Cells. 2020 , 5, 32907-32918	1
703	The Effect of Place of Residence on Treatment Outcomes and Survival in Octogenarian and Nonagenarian Breast Cancer Patients. 2020 , 12, e11934	
702	Evaluation of early post-natal pig mammary gland development and human breast cancer gene expression. 2022 , 481, 95-103	3
701	The Explanation Game: A Formal Framework for Interpretable Machine Learning. 2021 , 109-143	
700	The Explanation Game: A Formal Framework for Interpretable Machine Learning. 2021 , 185-219	2
699	Metabolomic profiling of mouse mammary tumor derived cell lines reveals targeted therapy options for cancer subtypes.	0

698 Genomics and Bioinformatics in Biological Discovery and Pharmaceutical Development. **2020**, 105-142

697 Evaluating Deep Semi-supervised Learning for Whole-Transcriptome Breast Cancer Subtyping. **2020**, 232-244

696 The Immune Landscape in Women Cancers. **2020**, 180, 215-249

1

695 Hypercluster: a python package and SnakeMake pipeline for flexible, parallelized unsupervised clustering optimization.

1

694 and Phenotype Presentation of Breast Cancer with a Special Focus on High-Risk Women. **2020**, 113-130

693 Ki-67 in breast cancer:. **2020**, 57, 231-233

692 Cell Cycle, DNA Replication, Centrosomes, Centrioles and Cell Division. **2020**, 667-742

691 Surrogate molecular classification of breast carcinoma: A classification in need or a dilemma indeed. **2020**, 4, 79

690 Survival outcomes are associated with genomic instability in luminal breast cancers.

689 Estrogen receptor expression in normal breast epithelium in invasive ductal carcinoma.

688 Denoising large-scale biological data using network filters.

687 Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. **2020**, 15, 30-49

1

686 Hormone Receptor-status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape.

685 The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer.

684 Molecular subtypes of bladder cancer and first success in personalized treatment. **2020**, 16, 106-113

683 Targeting subtype-specific metabolic preferences in nucleotide biosynthesis inhibits tumor growth in a breast cancer model.

682 Combined use of absolutely quantitated cyclin D1 and Ki67 protein levels to improve prognosis of Luminal-like breast cancer.

681 . **2021**,

O

- 680 Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer.. **2022**, 29, 1808-1812 1
- 679 Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients. **2021**, 11, 737794 0
- 678 Density-dependent migration characteristics of cancer cells driven by pseudopod coordination. 1
- 677 The role of ferroptosis-related genes for overall survival prediction in breast cancer. **2021**, 35, e24094 2
- 676 Prädiktive und prognostische Faktoren in der Therapie des frühen Mammakarzinoms. **2021**, 27, 1175
- 675 Natural phytochemicals as testable therapeutic alternatives for HER-2-enriched breast cancer (Review). 0
- 674 Linking Interactome to Disease. 151-172
- 673 Molecular markers in breast cancer: current practice and future possibilities. **2005**, 563, 35-41 0
- 672 Cancer Diagnosis. 427-447
- 671 Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. **2006**, 205-220
- 670 Endocrine therapy of breast cancer. **2006**, 201-230
- 669 Dawn of a new era in molecular cancer therapeutics. **2005**, 63, 1-17 1
- 668 Chemosensitization. **2005**, 335-348
- 667 Molecular Biology Applications in Cardiovascular Medicine. **2005**, 11-43
- 666 Molecular Profiling in Breast Cancer. **2006**, 559-576
- 665 Targeted Therapy For Breast Cancer. **2008**, 309-342
- 664 DNA and Tissue Microarrays. **2007**, 98-108
- 663 Classification moléculaire des cancers du sein. Implications pratiques. **2007**, 289-295

662	Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Responsive Breast Cancer. 2006 , 327-348	
661	Metastatic Breast Cancer: Tailored Endocrine Therapy for Postmenopausal Women. 2006 , 465-477	
660	Genomic and Molecular Classification of Breast Cancer. 2006 , 595-621	
659	Progress in the Treatment of Early and Advanced Breast Cancer. 2008 , 239-256	
658	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. 2008 , 15-32	
657	Network-Based Inference of Cancer Progression from Microarray Data. 2008 , 268-279	1
656	Analysis of Array Data and Clinical Validation of Array-Based Assays. 2012 , 171-210	0
655	Integrative, multi-omics, analysis of blood samples improves model predictions: applications to cancer.	
654	A topic modelling analysis of TCGA breast and lung cancer transcriptomic data.	
653	A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.	
652	Kinase-substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer. 2020 , 18, 525-538	
651	Integrative clustering methods for high-dimensional molecular data. 2014 , 3, 202-216	20
650	Differential Association of the Lifestyle-Related Risk Factors Smoking and Obesity with Triple Negative Breast Cancer in a Brazilian Population. 2017 , 18, 1585-1593	6
649	The breast. 571-687	1
648	Clinical proteomics: present and future prospects. 2006 , 27, 99-116	50
647	Breast cancer clinical and translational research: analogies and implications for prostate cancer. 2007 , 9 Suppl 2, S28-39	1
646	Mechanisms of oncogenic cooperation in cancer initiation and metastasis. 2006 , 79, 95-103	27
645	Public databases and software for the pathway analysis of cancer genomes. 2007 , 3, 379-97	6

644	Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. 2009 , 16, 56-8	4
643	Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. 2009 , 2, 444-55	63
642	Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns. 2007 , 2, 243-74	9
641	Integrative analysis of gene expression data including an assessment of pathway enrichment for predicting prostate cancer. 2007 , 2, 289-300	3
640	State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments. 2005 , 3, Doc08	4
639	Trastuzumab in the management of early and advanced stage breast cancer. 2007 , 1, 19-31	31
638	From bench to bedside: the growing use of translational research in cancer medicine. 2010 , 2, 1-18	48
637	Understanding and treating triple-negative breast cancer. 2008 , 22, 1233-9; discussion 1239-40, 1243	167
636	p16INK4a expression in basal-like breast carcinoma. 2010 , 3, 600-7	18
635	Technology as a force for improved diagnosis and treatment of breast disease. 2010 , 53, 268-77	18
634	Does race affect outcomes in triple negative breast cancer?. 2010 , 4, 23-33	15
633	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. 2010 , 4, 35-41	389
632	BeadDataPackR: A Tool to Facilitate the Sharing of Raw Data from Illumina BeadArray Studies. 2010 , 9, 217-27	1
631	Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy. 2010 , 2, 191-202	19
630	The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective. 2010 , 1, 84-91	2
629	Systems approaches to molecular cancer diagnostics. 2010 , 10, 531-42	5
628	The nuclear epidermal growth factor receptor signaling network and its role in cancer. 2011 , 12, 419-32	143
627	Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. 2012 , 5, 806-13	36

626	Association of estrogen receptor- α 908G (K303R) mutation with breast cancer risk. 2013 , 6, 39-49	16
625	Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. 2012 , 24, 388-98	14
624	Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. 2012 , 14, 102-9	12
623	Correlation of tumor-infiltrating lymphocytes to histopathological features and molecular phenotypes in canine mammary carcinoma: A morphologic and immunohistochemical morphometric study. 2013 , 77, 142-9	5
622	Classification of breast carcinomas according to gene expression profiles. 2013 , 6, 14-7	7
621	YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression. 2007 , 2, 49-65	34
620	Determination of whole transcription profiles and specific pathways in invasive ductal breast carcinoma. 2013 , 6, 1112-20	3
619	Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer. 2013 , 3, 446-64	11
618	Expression of metabolism-related proteins in triple-negative breast cancer. 2014 , 7, 301-12	11
617	Differential Expression of Key Signaling Proteins in MCF10 Cell Lines, a Human Breast Cancer Progression Model. 2012 , 4, 31-40	33
616	Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer. 2013 , 6, 165-73	3
615	ID4: a new player in the cancer arena. 2010 , 1, 48-58	24
614	Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. 2014 , 7, 5203-9	13
613	Male breast carcinoma: a clinicopathological and immunohistochemical characterization study. 2014 , 7, 6852-61	6
612	Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients. 2014 , 7, 7915-22	7
611	Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders. 2015 , 132-43	43
610	Dihydroartemisinin inhibits cell proliferation via AKT/GSK3 β /cyclinD1 pathway and induces apoptosis in A549 lung cancer cells. 2014 , 7, 8684-91	31
609	Dedifferentiation-like progression of breast carcinoma: report of a case showing transition from luminal-type carcinoma to triple-negative carcinoma with myoepithelial features. 2015 , 8, 2117-22	1

608	Spectral clustering strategies for heterogeneous disease expression data. 2013 , 212-23	4
607	Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients. 2015 , 8, 7059-71	10
606	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. 2015 , 7, 1009-20	28
605	DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition. 2015 , 5, 2113-26	19
604	Prognostic effect analysis of molecular subtype on young breast cancer patients. 2015 , 27, 428-36	10
603	Breast cancer intrinsic subtype classification, clinical use and future trends. 2015 , 5, 2929-43	296
602	Expression of CCL2 is significantly different in five breast cancer genotypes and predicts patient outcome. 2015 , 8, 15684-91	14
601	Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. 2015 , 8, 15184-90	7
600	Antibody Therapeutics in Oncology. 2016 , 2,	9
599	The potential for liquid biopsies in the precision medical treatment of breast cancer. 2016 , 13, 19-40	10
598	Prognostic signatures of breast cancer: Perou's molecular subtypes and Schmidt's metagenes. 2012 , 11, 204-7	4
597	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. 2016 , 6, 1609-23	115
596	Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation. 2016 , 6, 2129-2139	27
595	Enabling Comprehension of Patient Subgroups and Characteristics in Large Bipartite Networks: Implications for Precision Medicine. 2017 , 2017, 21-29	3
594	Triple Negative Breast Cancer at the University Hospital Mohammed VI à Dujda. 2017 , 18, 195-200	2
593	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. 2010 , 8, 101-111	1
592	Descriptive study of triple negative breast cancer in Eastern Algeria. 2018 , 29, 45	2
591	Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses. 2018 , 10, 1677-1689	6

590	Prolactin-induced protein (PIP)-characterization and role in breast cancer progression. 2018 , 8, 2150-2164	11
589	Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers. 2017 , 18, 1617-1621	2
588	Overweight: Is It a Prognostic Factor in Women with Triple-Negative Breast Cancer?. 2017 , 18, 1519-1523	8
587	Extract Triggers Apoptosis and Down-Regulates Gene Expression in Breast Cancer Cell Lines. 2019 , 8, 119-125	1
586	Clinicopathologic characteristics of HER2-positive pure mucinous breast carcinoma: a systematic investigation into an unusual tumor. 2019 , 12, 1666-1677	2
585	Prolactin and androgen R1881 induce pro-survival carboxypeptidase-D and EDD E3 ligase in triple-negative and HER2+ breast cancer. 2020 , 10, 1321-1343	2
584	Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis. 2021 , 14, 322-337	1
583	An association between chronic life stressors prior to diagnosis of breast cancer. 2021 , 20, 1370-1378	
582	Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.. 2021 , 11, 769280	3
581	Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update. 2021 , 22,	4
580	Identifying prognostic signatures in the microenvironment of prostate cancer.. 2021 , 10, 4206-4218	1
579	Gene Methylation in Circulating Cell-Free DNA from the Blood Plasma as Prognostic and Predictive Factor in Breast Cancer. 2021 , 57, 1239-1252	0
578	Optimization algorithm for omic data subspace clustering.	
577	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. 2021 , 13,	6
576	A deep matrix factorization framework for identifying underlying tissue-specific patterns of DCE-MRI: applications for molecular subtype classification in breast cancer. 2021 , 66,	
575	Value of F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype. 2021 , 11, 116	0
574	A Possible Perspective about the Compositional Models, Evolution, and Clinical Meaning of Human Enterotypes. 2021 , 9,	1
573	Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. 2021 , 11, 774088	2

572	Gene Co-Expression in Breast Cancer: A Matter of Distance. 2021 , 11, 726493	0
571	Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. 2021 ,	4
570	MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer. 2021 , 13,	2
569	The effects and possible mechanism of action of apolipoprotein M on the growth of breast cancer cells. 2021 , 1	0
568	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. 2021 , 10, 77	0
567	Aquaporin-1 in breast cancer. 2021 ,	2
566	Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. 2021 , 131,	1
565	Frühes Mammakarzinom: Exzellente Heilungsraten bei wenig aggressiver Therapie.	
564	Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy. 2021 , 68, 213-219	2
563	Analysis of the correlation between key gene mutations and breast cancer. 2021 , 15, 174830262110311	
562	Involvement of Par-4 in Breast Cancer. 2021 , 113-131	
561	Loss of function of GATA3 induces basal-like mammary tumors.. 2022 , 12, 720-733	0
560	A Pan-Cancer Analysis of Tumor-Infiltrating B Cell Repertoires.. 2021 , 12, 790119	0
559	Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy.. 2022 , 14,	1
558	Biomarkers in Breast Carcinomas. 2022 , 309-333	
557	Regulation of the tumor suppressor PTEN in triple-negative breast cancer.. 2021 , 527, 41-48	5
556	The impact of young age at diagnosis (age . 2021 , 61, 77-83	5
555	Revisiting Feature Selection with Data Complexity. 2020 ,	1

- 554 Comprehensive analysis of the gene family functions in breast cancer.. **2020**, 9, 6369-6382 1
- 553 Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.. **2020**, 9, 7323-7336
- 552 Clinic, pathologic and molecular landscapes in ultra-young women with breast cancer in the State of S  Paulo: a real-world study. 31,
- 551 Optimization algorithm for omic data subspace clustering. **2021**,
- 550 Flimma: a federated and privacy-aware tool for differential gene expression analysis.. **2021**, 22, 338 2
- 549 The TSH/Thyroid Hormones Axis and Breast Cancer.. **2022**, 11, 0
- 548 Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors.. **2022**, 38, 110278 2
- 547 Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.. **2022**, 23, 11
- 546 Phytochemicals in Breast Cancer-Induced Osteoclastogenesis and Bone Resorption: Mechanism and Future Perspective. 1
- 545 Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer.. **2022**, 12, 1
- 544 Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.. **2022**, 1
- 543 Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using Cell Culture Uptake-Efflux Experiments.. **2021**, 8, 746532 1
- 542 The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer.. **2022**, 232, 95-100 1
- 541 A deep learning model for breast ductal carcinoma in situ classification in whole slide images.. **2022**, 1 0
- 540 Hormonal and Targeted Treatments in Breast Cancer. **2022**, 443-463 2
- 539 AIE-active macromolecules: designs, performances, and applications. **2021**, 13, 8-43 1
- 538 Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria.. **2022**, 25, 97-104 1
- 537 Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?. **2022**, 192, 343 4

536	Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes.. 2022 , 12, 693	2
535	Tumour Markers, Prognostic and Predictive Factors in Breast Cancer. 2022 , 221-241	1
534	Breast cancer stem cell population in different molecular subtypes of breast cancer.. 2022 , 41, 199-203	1
533	Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.. 2022 , 24, 8	0
532	Ultrasonographic morphological characteristics determined using a deep learning-based computer-aided diagnostic system of breast cancer.. 2022 , 101, e28621	0
531	Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.. 2022 , 24, 4	1
530	The functions and prognostic value of Kr��pel-like factors in breast cancer.. 2022 , 22, 23	1
529	A Pan-Cancer Analysis of the Oncogenic Role of Nuclear Transport Factor 2 in Human Cancers.. 2022 , 12, 829389	1
528	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. 2022 ,	4
527	How we treat HR-positive, HER2-negative early breast cancer.. 2022 ,	0
526	Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer.. 2022 , 12, 729	3
525	Stabilization of E-cadherin adhesions by COX-2/GSK3��signaling is a targetable pathway in metastatic breast cancer.	
524	Terapia personalizada en c��ncer de mama precoz. Implicancias pr��cticas. 2022 , 33, 17-24	
523	Transcribed Ultraconserved Regions Are Associated with Clinicopathological Features in Breast Cancer.. 2022 , 12,	1
522	The expression of is correlated with tumor-infiltrating immune cells in basal-like breast cancer and serves as a prognostic biomarker.. 2022 , 10, 81	
521	YB-1 Protein in Breast Cancer (Scientific and Personal Meetings with Professor Ovchinnikov).. 2022 , 87, S86-S47	
520	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer.. 2022 ,	0
519	The combination of TRAIL and the Smac mimetic LCL-161 induces an irreversible phenotypic change of MCF-7 breast cancer cells.. 2022 , 125, 104739	

- 518 X Curso internacional de avances en Oncolog a: investigaci n y nuevos f rmacos. **2003**, 5, 98-110
- 517 A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.. **2022**, 12, 2211
- 516 From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer.. **2021**, 11, 819565 1
- 515 Mass cytometric and transcriptomic profiling of epithelial-mesenchymal transitions in human mammary cell lines.. **2022**, 9, 44 2
- 514 Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer.. **2022**, 2022, 5621441 1
- 513 The 3D in vivo chorioallantoic membrane model and its role in breast cancer research.. **2022**, 1 0
- 512 Autophagy-related prognostic signature for survival prediction of triple negative breast cancer.. **2022**, 10, e12878
- 511 Identification of Halogen-Based Derivatives as Potent Inhibitors of Estrogen Receptor Alpha of Breast Cancer: An In-Silico Investigation. 1-25 1
- 510 The usefulness of sparse k-means in metabolomics data: An example from breast cancer data.
- 509 Special Considerations in Patients with Early-Stage Breast Cancer and Survivors.. **2022**, 49, 195-208 0
- 508 HLA Class II Histocompatibility Antigen  Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.. **2021**, 13, 0
- 507 : A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.. **2022**, 16, 11782234211059931 0
- 506 Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer.. **2022**, 55, e11857
- 505 Estrogen Receptor  Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?. **2022**, 3
- 504 Diverse roles of tumor-stromal PDGFB-to-PDGFR signaling in breast cancer growth and metastasis.. **2022**, 154, 93-140 1
- 503 [Is there a claudin-low phenotype of breast cancer?]. **2022**, 84, 45-49 0
- 502 Oxidative stress and its biological significance. **2022**, 27-76
- 501 Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives.. **2022**, 12, 0

500 Modeling and Interpreting Patient Subgroups in Hospital Readmission: Visual Analytical Approach.

499 CD81 partners with CD44 in promoting exosome biogenesis, tumor cluster formation, and lung metastasis in triple negative breast cancer.

498 Unconventional protein post-translational modifications: the helmsmen in breast cancer.. **2022**, 12, 22

1

497 Multiomics Topic Modeling for Breast Cancer Classification.. **2022**, 14,

0

496 Transcriptional Factor Repertoire of Breast Cancer in 3D Cell Culture Models.. **2022**, 14,

1

495 Modeling and Interpreting Patient Subgroups in Hospital Readmission: Visual Analytical Approach (Preprint).

494 Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET.. **2022**, 10,

0

493 Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. **2022**, 13, 896

4

492 De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.. **2022**,

0

491 The extended concurrent genes signature for disease-free survival in breast cancer.. **2022**,

0

490 KCTD15 Is Overexpressed in her2+ Positive Breast Cancer Patients and Its Silencing Attenuates Proliferation in SKBR3 CELL LINE.. **2022**, 12,

2

489 Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.. **2022**, 22, 167

0

488 Predicting the total PAHs concentrations in sediments from selected congeners using a multiple linear relationship.. **2022**, 12, 3334

487 Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.. **2022**, 12, 856974

4

486 Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy.. **2022**, 14,

2

485 The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature.. **2022**, 10,

0

484 The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.. **2022**, 29, 1761-1772

0

483 INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.. **2022**, 24, 18

0

482	Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis.. 2022 , 12, 813462	0
481	Development of a Model System to Study Expression Profile of RAC2 Gene in Breast Cancer MDA-MB-231 Cell Line.. 2022 , 2022, 2077850	
480	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.. 2022 , 14,	1
479	Functional diversity in the RAS subfamily of small GTPases.. 2022 ,	1
478	Expression of Proteinase-activated Receptor 2 (PAR2) as a Correlate of Concern in Triple-negative Breast Cancer (TNBC). 2022 , Publish Ahead of Print,	
477	27-Hydroxycholesterol Binds GPER and Induces Progression of Estrogen Receptor-Negative Breast Cancer.. 2022 , 14,	0
476	Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study.. 2022 ,	0
475	Canine and murine models of osteosarcoma.. 2022 , 3009858221083038	1
474	Biosensors as diagnostic tools in clinical applications.. 2022 , 188726	0
473	Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint.. 2022 , 27,	8
472	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment.. 2022 , 12, 866014	4
471	Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States.. 2022 , 16, 95	1
470	Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications.. 2022 ,	7
469	Gene Expression Changes by Diallyl Trisulfide Administration in Chemically-induced Mammary Tumors in Rats.. 2022 , 27, 22-30	
468	Epithelial-Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer.. 2022 , 15, 3497-3515	0
467	Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.. 2022 , 64, 1-6	0
466	BTG2 as a tumor target for the treatment of luminal A breast cancer.. 2022 , 23, 339	0
465	The ability to classify patients based on gene-expression data varies by algorithm and performance metric.. 2022 , 18, e1009926	0

464	Receipt of breast conservation over mastectomy in Black women- does breast cancer subtype matter?. 2022 ,	
463	MCL-1 is a clinically targetable vulnerability in breast cancer.. 2022 , 1-17	2
462	Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.. 2022 , 10, 337	0
461	Effect of combining CBD with standard breast cancer therapeutics. 2022 , 100038	0
460	Controlled Drug Release of Smart Magnetic Self-Assembled Micelle, Kinetics and Transport Mechanisms.. 2022 ,	1
459	Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.. 2022 , 1	
458	NSMCE2, a Novel Super-Enhancer Regulated Gene, is Linked to Poor Prognosis and Therapy Resistance in Breast Cancer.	
457	Genome-wide analysis of somatic noncoding mutation patterns in cancer.. 2022 , 376, eabg5601	2
456	Effect of different molecular subtype reference standards in AI training: implications for DCE-MRI radiomics of breast cancers. 2022 ,	
455	Evaluation of volumetric breast density as a risk factor for breast carcinoma in pre- and postmenopausal women, its association with hormone receptor status and breast carcinoma subtypes defined by histology and tumor markers. 2022 , 53,	0
454	ER α isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups. 2022 , 44, 1564-1586	2
453	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.. 2022 , 39, 110595	2
452	Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer.. 2022 , 14,	0
451	Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.. 2022 , 533, 215600	0
450	AltWOA: Altruistic Whale Optimization Algorithm for feature selection on microarray datasets.. 2022 , 144, 105349	6
449	A distributed dynamic load identification method based on the hierarchical-clustering-oriented radial basis function framework using acceleration signals under convex-fuzzy hybrid uncertainties. 2022 , 172, 108935	1
448	A novel peptide-based electrochemical biosensor for breast cancer characterization over a poly 3-(3-aminophenyl) propionic acid matrix.. 2022 , 205, 114081	2
447	Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.. 2022 , 31, 34-38	

- 446 Subclonal heterogeneity and evolution in breast cancer.. **2021**, 7, 155 3
- 445 Breast Cancer Cell Subtypes Display Different Metabolic Phenotypes That Correlate with Their Clinical Classification.. **2021**, 10, 1
- 444 Molecular Mechanisms of Biologically Active Compounds from Propolis in Breast Cancer: State of the Art and Future Directions. 1-38
- 443 Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.. **2022**, 23, 46 0
- 442 Unsupervised Algorithms for Microarray Sample Stratification.. **2022**, 2401, 121-146
- 441 YB1 Is a Major Contributor to Health Disparities in Triple Negative Breast Cancer.. **2021**, 13, 0
- 440 A probabilistic model for pathway-guided gene set selection. **2021**,
- 439 Identifying Cancer Subtypes Using a Residual Graph Convolution Model on a Sample Similarity Network.. **2021**, 13, 0
- 438 Determination of signature genes of breast cancer subtypes evaluated by clinical criteria using biclustering algorithm. **2021**,
- 437 Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.. **2021**, 0
- 436 Multi-omics Topic Modeling for Breast Cancer Classification.
- 435 High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer. **2021**, 21, 1305 2
- 434 Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer.. **2021**, 14, 0
- 433 Pathology of Neoadjuvant Systemic Therapy Response. **2022**, 269-290
- 432 Integration of DNA Microarray with Clinical and Genomic Data.. **2022**, 2401, 239-248
- 431 Molecular analysis of TCGA breast cancer histologic types.. **2021**, 1, 2
- 430 ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.. **2022**, 13, 2011 0
- 429 Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.. **2022**, 0

- 428 Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.. **2022**, 8, 51 0
- 427 Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit.. **2022**, 1
- 426 Non-Coding RNAs Are Brokers in Breast Cancer Interactome Networks and Add Discrimination Power between Subtypes.. **2022**, 11,
- 425 The ELEANOR non-coding RNA expression contributes to cancer dormancy and predicts late recurrence of ER-positive breast cancer.. **2022**, 1
- 424 Establishment of a New Cell Line of Canine Inflammatory Mammary Cancer: IMC-118.. **2022**,
- 423 Some Bayesian biclustering methods: Modeling and inference.
- 422 Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and Blueprint to guide preoperative systemic treatment decisions.. **2022**, 167, 92-102 0
- 421 Deregulated signaling networks in lung cancer. 421-442
- 420 Prognosis of cancer. 473-498
- 419 Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517
- 418 Prognostic and Predictive Value of TP53 Mutations in Human Cancer. **2007**, 321-338
- 417 Cancer Pharmacogenomics. **2005**, 339-357
- 416 DataSheet_1.pdf. **2019**,
- 415 Data_Sheet_1.XLSX. **2018**,
- 414 Data_Sheet_2.XLSX. **2018**,
- 413 Image_1.PDF. **2018**,
- 412 Image_2.PDF. **2018**,
- 411 Table_1.docx. **2018**,

410 Table_2.DOCX. **2018**,

409 Table_3.PDF. **2018**,

408 Data_Sheet_1.pdf. **2018**,

407 Table_1.xlsx. **2018**,

406 Table_2.xlsx. **2018**,

405 DataSheet_1.pdf. **2019**,

404 Data_Sheet_1.PDF. **2020**,

403 Data_Sheet_1.PDF. **2020**,

402 DataSheet_1.docx. **2019**,

401 Data_Sheet_1.PDF. **2020**,

400 Table_1.XLS. **2018**,

399 Image_1.TIFF. **2020**,

398 Image_2.TIFF. **2020**,

397 Table_1.XLS. **2020**,

396 Table_2.XLS. **2020**,

395 Image_1.tif. **2020**,

394 Table_1.docx. **2020**,

393 Data_Sheet_1.docx. **2020**,

392 Data_Sheet_1.pdf. **2019**,

391 DataSheet_1.pdf. **2020**,

390 Table_1.docx. **2020**,

389 Table_2.docx. **2020**,

388 Table_3.docx. **2020**,

387 Table_1.XLSX. **2019**,

386 Table_2.DOCX. **2019**,

385 Table_3.XLS. **2019**,

384 Table_1.DOCX. **2019**,

383 Data_Sheet_1.doc. **2018**,

382 Data_Sheet_1.docx. **2020**,

381 Table_1.docx. **2020**,

380 Table_2.docx. **2020**,

379 Image_1.png. **2020**,

378 Table_1.docx. **2020**,

377 Table_2.docx. **2020**,

376 Image_1.pdf. **2020**,

375 Image_2.pdf. **2020**,

374 Image_3.pdf. **2020**,

373 Image_4.pdf. **2020**,

372 Image_5.pdf. **2020**,

371 Image_6.pdf. **2020**,

370 Image_7.pdf. **2020**,

369 Table_1.pdf. **2020**,

368 Data_Sheet_1.docx. **2018**,

367 Data_Sheet_1.xlsx. **2020**,

366 Image_1.TIF. **2020**,

365 Image_2.TIF. **2020**,

364 Image_3.TIF. **2020**,

363 Image_4.TIF. **2020**,

362 Image_5.TIF. **2020**,

361 S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.. **2021**, 83, 683-696

360 Comprehensive comparison of theranostic nanoparticles in breast cancer.. **2022**, 11, 1-27

359 Triple-negative breast cancer - an aggressive subtype of breast cancer. **2022**, 1-28

358 Precision diagnostics in cancer: Predict, prevent, and personalize. **2022**,

357 Progress in nanotechnology-based targeted cancer treatment. **2022**, 239-250

- 356 Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.. **2022**, 29, 10732748221099230 0
- 355 Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 1-27
- 354 Modeling and Interpreting Patient Subgroups in Hospital Readmission: Visual Analytical Approach.. **2022**, 0
- 353 An Update on the Effect of Natural Products on Oncogenic Transcription Factors in Triple Negative Breast Cancer. **2022**, 1-26
- 352 Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.. **2022**, 6, e2100463 1
- 351 Density-Dependent Migration Characteristics of Cancer Cells Driven by Pseudopod Interaction.. **2022**, 10, 854721 0
- 350 Polyamines in cancer: integrating organismal metabolism and antitumour immunity.. **2022**, 10
- 349 The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy.. **2022**, 23, 0
- 348 Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. **2022**, 14, 2404
- 347 Comprehensive Landscape of STEAP Family Members Expression in Human Cancers: Unraveling the Potential Usefulness in Clinical Practice Using Integrated Bioinformatics Analysis. **2022**, 7, 64 2
- 346 Muscarinic Receptors Associated with Cancer.. **2022**, 14,
- 345 Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue. **2022**, 14, 977 0
- 344 CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.. **2022**, 13, 2642 0
- 343 Monocarboxylate transporter 1 is a novel target for breast cancer stem like-cell inhibition by diallyl trisulfide.. **2022**,
- 342 Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.. **2022**, 1
- 341 PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.. **2022**, 8, 61 0
- 340 Diffractaic acid, a novel TrxR1 inhibitor, induces cytotoxicity, apoptosis, and antimigration in human breast cancer cells.. **2022**, 361, 109984 1
- 339 Association between tumor F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.. **2022**, 12, 7858 0

- 338 Early-Stage Progression of Breast Cancer. **2022**, 113-123
- 337 Utility of Personalized Medicine in the Treatment of Different Subtypes of Breast Cancer. **2022**, 337-366
- 336 RHAMM expression tunes the response of breast cancer cell lines to hyaluronan.. **2022**, 0
- 335 Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer. **2022**, 9, 1
- 334 Fractionated irradiation of MCF7 breast cancer cells rewires a gene regulatory circuit towards a treatment-resistant stemness phenotype.. **2022**,
- 333 Sigmoid model analysis of breast dynamic contrast-enhanced MRI: Distinguishing between benign and malignant breast masses and breast cancer subtype prediction.. **2022**, e13651
- 332 Associations of coffee/caffeine consumption with postmenopausal breast cancer risk and their interactions with postmenopausal hormone use.. **2022**, 1
- 331 Adenoid Cystic Carcinoma of the Breast: A Case Report. **2022**,
- 330 Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. **2022**, 14, 2509 1
- 329 Wnt Signaling in the Breast: From Development to Disease. **2022**, 10, 1
- 328 Concepts in Breast Surgery. **2022**, 907-919
- 327 Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma—A Histopathological Study. **2022**, 58, 722
- 326 FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway. **2022**, 102082 0
- 325 Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. **2022**, 14, 2571 0
- 324 Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India. **2022**,
- 323 The Limits of Molecular Signatures for Pancreatic Ductal Adenocarcinoma Subtyping.
- 322 Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. **2022**, 14, 2578 2
- 321 Use of Radionuclide-Based Imaging Methods in Breast Cancer. **2022**, 0

- 320 High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. **2022**, 17, e0268799
- 319 PD-L1 (SP142 and 22C3) Immunohistochemistry in Clinical Metastatic Triple Negative or Low Hormone Receptor Breast Carcinomas: Experience from a Large Academic Institution. **2022**, 0
- 318 Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. **2022**, 12, e056374 0
- 317 Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer.
- 316 EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. **2022**, 23, 6122 0
- 315 Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective. **2022**, 29, 200-222 2
- 314 Identification of Crucial lncRNAs for Luminal A Breast Cancer through RNA Sequencing. **2022**, 2022, 1-14 0
- 313 The role of radiogenomics in the diagnosis of breast cancer: a systematic review. **2022**, 23, 2
- 312 Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (â) Breast Cancer. 13, 1
- 311 Molecular subtypes of breast carcinoma and its relation with clinicopathological features: A single-center initial experience. **2021**, 35, 103
- 310 How to Compare Various Clustering Outcomes? Metrics to Investigate Breast Cancer Patient Subpopulations Based on Proteomic Profiles. **2022**, 309-318
- 309 Translational Epidemiology in Cancer Research: The Less Travelled Path. **2022**, 349-366
- 308 CTCs/ctDNA and Brain Metastasis. **2022**, 157-166
- 307 The Role of Surgery in Managing Primary and Metastatic Breast Cancer. **2022**, 395-406
- 306 Breast. **2022**, 253-292
- 305 Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers. **2022**, 17, e0270139
- 304 A comprehensive bioinformatics analysis to identify potential prognostic biomarkers among CC and CXC chemokines in breast cancer. **2022**, 12, 0
- 303 Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis. 1

- 302 Examples of Inverse Comorbidity between Cancer and Neurodegenerative Diseases: A Possible Role for Noncoding RNA. **2022**, 11, 1930 o
- 301 Breast Cancer Genomics: Primary and Most Common Metastases. **2022**, 14, 3046
- 300 Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. **2022**, 17, e0268693 1
- 299 The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. **2022**, 11, 1195 o
- 298 Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant. **2022**, 8, o
- 297 Activation Versus Inhibition of IGF1R: A Dual Role in Breast Tumorigenesis. 13, o
- 296 Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification.
- 295 Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. 12, 4
- 294 omicsGAT: Graph Attention Network for Cancer Subtype Analyses.
- 293 Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. **2005**, 4, 151-170 17
- 292 The evolution of gene expression profiling in breast cancer âA narrative review. **2022**,
- 291 Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Phenotypes and Progress in Breast Cancer. **2022**, 401-424
- 290 A Novel YTHDF3-Based Model to Predict Prognosis and Therapeutic Response in Breast Cancer. 9, o
- 289 Role of germline variants in the metastasis of breast carcinomas. **2022**, 13, 843-862
- 288 A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. o
- 287 High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing. **2022**, 8, o
- 286 ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer. **2022**, 21, 135-142
- 285 Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

284	Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort. 2022 , 12,	1
283	MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer. 13,	0
282	Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach. 2022 , 12, 963	0
281	Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer. 2022 , 10, 46-52	
280	Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature. 2022 , 8,	0
279	Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism. 2022 , 10,	
278	Diagnosing molecular subtypes of breast cancer by means of Raman spectroscopy.	
277	Predictive biomarkers for personalized medicine in breast cancer. 2022 , 215828	0
276	Loss of RPTP β primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival.	
275	ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform. 2022 , 79,	0
274	The Clinicopathological Profile of Breast Cancer in Young Women from a Tertiary Care Center.	
273	Cellular and molecular mechanisms of breast cancer susceptibility. 2022 , 136, 1025-1043	
272	Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. 2022 , 8,	1
271	Fucoxanthinol Promotes Apoptosis in MCF-7 and MDA-MB-231 Cells by Attenuating LamininsâIntegrins Axis. 2022 , 2, 145-163	
270	Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. 2022 , 17,	2
269	Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. 2022 , 7, 100531	1
268	A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors. 2022 , 240, 114564	0
267	Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors. 2005 , 11, 380-389	7

- 266 Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles. **2004**, 3, 161-168 6
- 265 DNA Damage Response: A Therapeutic Landscape For Breast Cancer Treatment. **2022**, 62-85
- 264 Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. **2022**, 86-108
- 263 A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. **2022**, 8, 0
- 262 Contrast Subgraphs Allow Comparing Homogeneous and Heterogeneous Networks Derived from Omics Data.
- 261 The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer. **2022**, 10, 1843
- 260 Analyzing biomarker discovery: Estimating the reproducibility of biomarker sets. **2022**, 17, e0252697
- 259 Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer. 2
- 258 Cellular and Molecular Mechanisms of Breast Cancer Progression. **2022**, 1-21
- 257 Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. **2022**, 10, 1827 0
- 256 Dietary Polyphenols and its Molecular Mechanism in the Management of Breast Cancer. **2022**, 196-218
- 255 Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. **2022**, 14, 3876 2
- 254 TGFBR3 supports anoikis through suppressing ATF4 signaling.
- 253 An Overview Regarding Pharmacogenomics And Biomarkers Discovery: Focus On Breast Cancer. **2022**, 22, 0
- 252 Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. **2022**, 23, 8716 1
- 251 Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?. 2200238 2
- 250 PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. **2022**, 11, 2508 4
- 249 Atorvastatin Improves Cisplatin Sensitivity Through Modulation of Cholesteryl Ester Homeostasis in Breast Cancer Cells.

248	ALKBH family members as novel biomarkers and prognostic factors in human breast cancer.	2
247	Triple negative breast cancer: approved treatment options and their mechanisms of action.	1
246	Correlation of tumour subtype with long-term outcome in small breast carcinomas: a Swedish population-based retrospective cohort study.	1
245	Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. 10,	0
244	PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation.	0
243	A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome.	
242	A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.	0
241	Breast cancer stage prediction: a computational approach guided by transcriptome analysis.	
240	Distinctive gene expression patterns in pregnancy-associated breast cancer. 13,	1
239	BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.	
238	Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. 2022 , 5,	2
237	Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors.	0
236	In Vitro and In Silico Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells.	1
235	Relative importance of genotype, gene expression, and DNA methylation on complex traits in perennial ryegrass.	
234	Targeted proteomics using parallel reaction monitoring confirms salivary proteins indicative of metastatic triple-negative breast cancer. 2022 , 267, 104701	0
233	Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. 2022 , 349, 844-875	2
232	Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients. 2022 , 238, 154080	0
231	Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications. 2005 , 11, 878s-883s	4

- 230 Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between β and γ Integrins, E-Cadherin and HER-2. **2022**, 23, 10194 ○
- 229 Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. **2022**, 847, 146881 ○
- 228 Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer. **2022**, 6, 100065 ○
- 227 Biomarkers, Prognosis, and Prediction Factors. **2023**, 49-70 ○
- 226 DNA mikromatriser åtmålbrikker med store konsekvenser. **2002**, 112, ○
- 225 A comparison of tumor size with ultrasonography and magnetic resonance imaging and histopathology based on ductal carcinoma &in situ&/i> subtype. **2022**, 34, 125-132 ○
- 224 miRNA and mRNA Expression Analysis of Human Breast Cancer Subtypes to Identify New Markers. **2022**, 115-128 ○
- 223 The protein corona reduces the anticancer effect of graphene oxide in HER-2-positive cancer cells. **2022**, 4, 4009-4015 1
- 222 Pattern of local recurrence and metastasis in carcinoma breast according to molecular subtype in patients treated with definitive intent. **2022**, 0 ○
- 221 Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays. **2022**, 11-31 1
- 220 Role of Tumor-associated neutrophils in the breast tumor microenvironment. **2022**, 171-194 ○
- 219 Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. **2022**, 14, 175883592211180 1
- 218 Using classification and K-means methods to predict breast cancer recurrence in gene expression data. **2022**, 12, 122 ○
- 217 Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. **2022**, 171-194 ○
- 216 Identifying Phenotypic Concepts Discriminating Molecular Breast Cancer Sub-Types. **2022**, 276-286 ○
- 215 Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 715-741 ○
- 214 k-best feature selection and ranking via stochastic approximation. **2023**, 213, 118864 ○
- 213 Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. **2022**, 101, e29887 ○

212	Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. 2022 , 12, 1404	1
211	Comparison of Genomic Profiling Data with Clinical Parameters: Implications for Breast Cancer Prognosis. 2022 , 14, 4197	0
210	Development and testing of a polygenic risk score for breast cancer aggressiveness.	0
209	The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. 2022 , 14, 4203	0
208	Hybrid Feature Selection of Breast Cancer Gene Expression Microarray Data Based on Metaheuristic Methods: A Comprehensive Review. 2022 , 14, 1955	1
207	LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. 2022 , 13,	1
206	Time tracking and multidimensional influencing factors analysis on female breast cancer mortality: Evidence from urban and rural China between 1994 to 2019. 10,	0
205	omicsGAT: Graph Attention Network for Cancer Subtype Analyses. 2022 , 23, 10220	0
204	Divergence of mutational signatures in association with breast cancer subtype.	1
203	Modeling and simulation of smart magnetic self-assembled nanomicelle trajectories in an internal thoracic artery flow for breast cancer therapy.	0
202	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. 2022 , 41,	4
201	Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.	0
200	Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma. 2022 , 11, 2924	0
199	miR -92a-3p promotes breast cancer proliferation by regulating the KLF2 / BIRC5 axis.	0
198	Relative quantification of proteins in formalin-fixed paraffin-embedded breast cancer tissue using multiplexed mass spectrometry assays. 2022 , 100416	0
197	Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- β receptors. 2022 , 13,	0
196	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13,	2
195	A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. 12,	0

194	Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations. 2022 , 39,	0
193	Molecular Classification of Breast Cancer. 2022 ,	0
192	Recursive integration of synergised graph representations of multi-omics data for cancer subtypes identification. 2022 , 12,	0
191	Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. 13,	0
190	Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq. 2022 , 23, 9936	1
189	The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry. Publish Ahead of Print,	1
188	Biologically relevant integration of transcriptomics profiles from cancer cell lines, patient-derived xenografts and clinical tumors using deep learning.	0
187	Paired evaluation defines performance landscapes for machine learning models.	0
186	Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm. 2022 , 14, 4663	0
185	The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer. 12,	0
184	In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents.	0
183	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. 2022 , 23, 11046	1
182	Acquisition of hybrid E/M phenotype associated with increased migration, drug resistance and stemness is mediated by reduced miR-18a levels in ER-negative breast cancer.	0
181	Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study. 2022 , 18, 315-322	0
180	Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. 11,	1
179	Prognosis of lasso-like penalized Cox models with tumor profiling improves prediction over clinical data alone and benefits from bi-dimensional pre-screening. 2022 , 22,	1
178	Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. 2022 , 54, 2581-2597	2
177	The Distinguishing Electrical Properties of Cancer Cells. 2022 ,	0

- 176 Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. **2022**, 18, 353-359 ○
- 175 Predicting hormone receptors and PAM50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique. **2022**, 150, 106147 1
- 174 Predictive value of Ki67 for complete pathological response to neoadjuvant chemotherapy in patients with breast cancer. **2021**, 41, 194 ○
- 173 Câncer de mama e sistema purinéfico. **2021**, 138-155 ○
- 172 The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping. **2022**, 4, ○
- 171 NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. **2022**, 22, 1
- 170 The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12, ○
- 169 Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients. **2022**, 14, 4844 ○
- 168 Cancer Genomics and Evolution. 1-30 ○
- 167 Cell Adhesion Molecules Affected by Ionizing Radiation and Estrogen in an Experimental Breast Cancer Model. **2022**, 23, 12674 ○
- 166 Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer. **2022**, 14, 5241 ○
- 165 Cellular Plasticity and Heterotypic Interactions during Breast Morphogenesis and Cancer Initiation. **2022**, 14, 5209 1
- 164 The Transcriptomic Landscape of Pediatric Astrocytoma. **2022**, 23, 12696 ○
- 163 Bi-EB: Empirical Bayesian Biclustering for Multi-Omics Data Integration Pattern Identification among Species. **2022**, 13, 1982 ○
- 162 Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. **2022**, 24, ○
- 161 6. Relationships between Histomorphology, Imaging Findings and Subtypes in Breast Cancer. **2022**, 78, 1224-1229 ○
- 160 DNA Methylation Signatures in Breast Cancer: A Systematic Review and Meta-Analysis. ○
- 159 Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification. ○

- 158 Intrinsic subtypes in Ethiopian breast cancer patient. **2022**, 196, 495-504 o
- 157 Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. **2022**, 14, 4829 2
- 156 A genomic and transcriptomic study toward breast cancer. 13, o
- 155 A Robust Personalized Classification Method for Breast Cancer Metastasis Prediction. **2022**, 14, 5327 o
- 154 HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. **2022**, 22, o
- 153 USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1. **2022**, 11, 3294 o
- 152 Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer. 12, o
- 151 K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. **2022**, 14, 5322 o
- 150 Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s). 2
- 149 Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells. **2022**, 23, 11887 o
- 148 Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes. o
- 147 Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: a systematic review. **2022**, 2
- 146 Neighborhood and Racial Influences on Triple Negative Breast Cancer: Evidence from Northeast Ohio. o
- 145 Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers. o
- 144 Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics. **2022**, 14, 5507 2
- 143 An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer. o
- 142 Atorvastatin Improves Cisplatin Sensitivity Through Modulation of Cholesteryl Ester Homeostasis in Breast Cancer Cells. o
- 141 Jackstraw inference for AJIVE data integration. **2022**, 107649 o

- 140 MLSP: A Bioinformatics Tool for Predicting Molecular Subtypes and Prognosis in Patients with Breast Cancer. **2022**, 0
- 139 Co-expression of Matrix Metalloproteinase 9 (MMP9) and Motility-related Protein-1 (MRP-1/CD9) in Human Breast Cancer. **2022**, 15, 0
- 138 The application of exosomes in the treatment of triple-negative breast cancer. 9, 0
- 137 Single-cell imaging based prognosis prediction identifies new breast cancer survival subtypes. 0
- 136 CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3. **2022**, 14, 5453 1
- 135 Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. **2022**, 12, 32956-32978 0
- 134 Antitumor effect of melatonin on breast cancer in experimental models: A systematic review. **2022**, 188838 1
- 133 Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. **2022**, 14, 5668 1
- 132 Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. **2022**, 895-915 0
- 131 Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. **2023**, 112, 102496 0
- 130 Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. 0
- 129 Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER +/- HER2 Breast Cancer Quantified With 21-Gene Recurrence Score. 0
- 128 High SURF4 expression is associated with poor prognosis of breast cancer. **2022**, 14, 9317-9337 0
- 127 ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells. **2022**, 14, 5890 0
- 126 The POLR3G Subunit of Human RNA Polymerase III Regulates Tumorigenesis and Metastasis in Triple-Negative Breast Cancer. **2022**, 14, 5732 0
- 125 Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. **2022**, 13, 0
- 124 Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery. **2022**, 14, 5761 0
- 123 Is it possible to identify subpopulations of triple negative breast cancer?. **2022**, 13, 352-360 0

122	Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. Publish Ahead of Print,	0
121	Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis. 2022 , 11, 6987	0
120	Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers. 2022 , 17,	0
119	Transcriptomic pan-cancer analysis using rank-based Bayesian inference.	0
118	Identifying Associations between DCE-MRI Radiomic Features and Expression Heterogeneity of Hallmark Pathways in Breast Cancer: A Multi-Center Radiogenomic Study. 2023 , 14, 28	0
117	Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer. 13,	0
116	Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study.	1
115	Long term trends of breast cancer incidence according to proliferation status. 2022 , 22,	0
114	Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. 2022 , 12,	0
113	Update on triple-negative breast cancers âhighlighting subtyping update and treatment implication. 2023 , 82, 17-35	2
112	Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. 12,	0
111	Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines. 2023 , 40,	0
110	AKTIP loss is enriched in ER α -positive breast cancer for tumorigenesis and confers endocrine resistance. 2022 , 41, 111821	0
109	Development and characterization of a recombinant silk network for 3D culture of immortalized and fresh tumor-derived breast cancer cells.	0
108	Long-term oncological outcomes of organ-sparing treatment of patients with early breast cancer aged 65 years and older who had no postoperative radiation therapy. 2022 , 18, 24-28	0
107	Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit.	0
106	Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells. 2022 , 13,	0
105	Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review. 12,	0

104	Blockade of Store-operated Calcium Entry Sensitizes Breast Cancer Cells to Cisplatin Therapy via Modulating Inflammatory Response. 2022 ,	0
103	Predicting transcription factor activity using prior biological information.	0
102	Hormone Receptors and HER-2 Status as Surrogates for Breast Cancer Molecular Subtypes Prognosticate for Disease Control in Node Negative Asian Patients Treated with Breast Conservation Therapy. 2011 , 40, 90-96	0
101	PI3K&AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. 2023 , 13, 93	1
100	Phenotypic subtyping via contrastive learning.	0
99	Etiological Insights into TNBC and their Related Catastrophic Risks. 2023 , 1-25	0
98	Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. 2023 , 12, 411	0
97	Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. 12,	0
96	Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts.	0
95	Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. 2023 , 47-72	0
94	On data normalization and batch-effect correction for tumor subtyping with microRNA data. 2023 , 5,	0
93	Differences in Molecular Subtype Reference Standards Impact AI-based Breast Cancer Classification with Dynamic Contrast-enhanced MRI.	0
92	Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. 2023 , 43,	0
91	The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. 2023 , 11, 98	0
90	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.	1
89	Genetic profiling of different phenotypic subsets of breast cancer stem cells (BCSCs) in breast cancer patients. 2022 , 22,	0
88	Mebendazole prevents distant organ metastases in part by decreasing ITGA expression and cancer stemness. 2022 , 24,	1
87	MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 - Early Breast Cancer Patients.	0

- 86 Personalized medicine. **2023**, 1-32 o
- 85 Molekularpathologie in der Gyn onkologie Beschreibung einer Revolution. o
- 84 Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 o
- 83 Tumour Growth Models of Breast Cancer for Evaluating Early Detection   Summary and a Simulation Study. **2023**, 15, 912 o
- 82 The WAVE2/miR-29/Integrin   Oncogenic Signaling Axis Promotes Tumor Growth and Metastasis in Triple-negative Breast Cancer. **2023**, 3, 160-174 o
- 81 Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes. **2023**, 11, 10912-10924 o
- 80 Subtyping Social Determinants of Health inAll of Us: Opportunities and Challenges in Integrating Multiple Datatypes for Precision Medicine. o
- 79 Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?. **2023**, 78, 100155 o
- 78 GRHL2-controlled gene expression networks in luminal breast cancer. **2023**, 21, o
- 77 The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. **2023**, 13, o
- 76 Distinct tumor architectures for metastatic colonization of the brain. o
- 75 Assessment of Projection Pursuit Index for Classifying High Dimension Low Sample Size Data in R. **2023**, 1-23 o
- 74 CORRELATION BETWEEN DIFFERENT CLINICOPATHOLOGICAL PARAMETERS AND MOLECULAR SUBTYPES OF FEMALE BREAST CARCINOMA IN SOUTH REGION OF IRAQ. **2023**, 76, 97-107 o
- 73 Introduction to Breast Cancer. **2023**, 1-22 o
- 72 Advanced Phytochemical-Based Nanocarrier Systems for the Treatment of Breast Cancer. **2023**, 15, 1023 o
- 71 Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts. o
- 70 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 o
- 69 High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer. o

- 68 Acetylacetone and imidazole coordinated Re(I) tricarbonyl complexes: Experimental, DFT studies, and molecular docking approach. **2023**, 6, 100165 o
- 67 Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment.. **2023**, 162, 114607 o
- 66 Charting spatial ligand-target activity using Renoir. o
- 65 Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. **2023**, 162, 114648 o
- 64 Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. **2023**, 8, 101214 o
- 63 Clinical Significance and Characteristics of Newly Detected Lesions on Breast MRI During Neoadjuvant Chemotherapy. **2022**, 26, 303 o
- 62 Molecular aspects of brain metastases in breast cancer. **2023**, 114, 102521 o
- 61 Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. **2023**, 23, 41-51 o
- 60 Metabolomics Profiling Reveals the Role of PEDF in Triple-Negative Breast Cancer Cell MDA-MB-231 under Glycaemic Loading. **2023**, 15, 543 o
- 59 Change Is Good: The Evolution and Future of Breast Imaging. **2023**, 306, 1
- 58 Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer. **2023**, 20, 2903 1
- 57 Molecular profiling in contemporary breast cancer management. o
- 56 Recent progress in gold and silver nanoparticle mediated drug delivery to breast cancers. **2023**, 291-328 o
- 55 Stabilization of E-cadherin adhesions by COX-2/GSK3 β signaling is a targetable pathway in metastatic breast cancer. **2023**, 8, o
- 54 Comprehensive analysis of NT5DC family prognostic and immune significance in breast cancer. **2023**, 102, e32927 o
- 53 Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio. **2023**, 198, 369-381 o
- 52 Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study. **2023**, 13, 694 o
- 51 The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers. **2023**, 9, 165-181 o

- 50 Breast cancer subtype and clinical characteristics in women from Peru. 13, ○
- 49 Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. **2023**, 133, ○
- 48 NUF2 Promotes Breast Cancer Development as a New Tumor Stem Cell Indicator. **2023**, 24, 4226 ○
- 47 Development and validation of nomograms to predict survival in patients with invasive micropapillary carcinoma of the breast. **2023**, 13, e065312 ○
- 46 Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer. **2023**, 12, 720 ○
- 45 Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. **2023**, 24, 4478 ○
- 44 KPT -330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF- κ B signaling. **2023**, 13, 751-762 ○
- 43 Cancer Diagnostics. **2023**, 459-481 ○
- 42 Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy. **2023**, 49-73 ○
- 41 Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. **2022**, 12, ○
- 40 Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. **2023**, 25, ○
- 39 Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions. **2023**, 25, 491-500 ○
- 38 Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer. 13, ○
- 37 Evaluation of the efficacy of chemotherapy for tubular carcinoma of the breast: A Surveillance, Epidemiology, and End Results cohort study. ○
- 36 Identification of Altered Transcripts and Pathways in Triple Negative Breast Cancer. **2023**, 77, 33-40 ○
- 35 Molecular subtypes of breast cancer: secular improvement in prognosis. ○
- 34 The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer. **2023**, 15, 1704 ○
- 33 Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4 / CyclinD1-pRB-E2F1 pathway. **2023**, 27, 991-1005 ○

- 32 Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. **2023**, 24, 5474 ○
- 31 Position paper on CDK4/6 inhibitors in early breast cancer. ○
- 30 Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. **2023**, 4, 100977 ○
- 29 SOLID LIPID NANOPARTICLES: A REVIEW ON DIFFERENT TECHNIQUES AND APPROACHES TO TREAT BREAST CANCER. 52-62 ○
- 28 Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93 ○
- 27 Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. **2023**, 80, ○
- 26 Intratumoral heterogeneity, treatment response, and survival outcome of ER -positive HER2 -positive breast cancer. ○
- 25 Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. ○
- 24 The WAVE3/Eatenin oncogenic signaling regulates chemoresistance in triple negative breast cancer. **2023**, 25, ○
- 23 Involvement of APOBEC3A/B Deletion in Mouse Mammary Tumor Virus (MMTV)-like Positive Human Breast Cancer. **2023**, 13, 1196 ○
- 22 Special Studies. **2013**, 279-304 ○
- 21 Invasive Breast Carcinomas. **2013**, 147-212 ○
- 20 Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. **2023**, 24, ○
- 19 A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy. **2023**, ○
- 18 Molecular breast cancer subtype identification using photoacoustic spectral analysis and machine learning at the biomacromolecular level. **2023**, 30, 100483 ○
- 17 GATA-3 expression in breast cancer is related to intratumoral M2 macrophage infiltration and tumor differentiation. **2023**, 18, e0283003 ○
- 16 TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. ○
- 15 Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An <i>In Silico</i> Approach. **2023**, 19, 148-158 ○

- 14 Compliance to adjuvant endocrine therapy and survival in breast cancer patients.. **2023**, 35, 100704 ○
- 13 Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors. ○
- 12 Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer. ○
- 11 Homotypic Entosis as a Potential Novel Diagnostic Marker in Breast Cancer. **2023**, 24, 6819 ○
- 10 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). ○
- 9 SRPKs: a promising therapeutic target in cancer. ○
- 8 Learning Vector Quantized Representation for Cancer Subtypes Identification. **2023**, 107543 ○
- 7 Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. ○
- 6 Withaferin A inhibits breast cancer-induced osteoclast differentiation. ○
- 5 Salivary gland neoplasms in small biopsies and fine needle aspirations. **2023**, ○
- 4 Multimodal ultrasound features of breast cancers: correlation with molecular subtypes. **2023**, 23, ○
- 3 Expression of type VI collagen β chain in canine mammary carcinomas. **2023**, ○
- 2 Sustained Shugoshin 1 downregulation reduces tumor growth and metastasis in a mouse xenograft tumor model of triple-negative breast cancer. **2023**, 18, ○
- 1 DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome. **2023**, 246, 154513 ○